[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 751
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol; 2007 Aug;114(2):97-109
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological variants were added if there was evidence of a different age distribution, location, genetic profile or clinical behaviour; these included pilomyxoid astrocytoma, anaplastic medulloblastoma and medulloblastoma with extensive nodularity.
  • As in the previous, 2000 edition of the WHO 'Blue Book', the classification is accompanied by a concise commentary on clinico-pathological characteristics of each tumour type.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Acta Neuropathol. 1995;89(4):385-90 [7610772.001]
  • [Cites] Acta Neuropathol. 1997 Aug;94(2):187-91 [9255395.001]
  • [Cites] Ann Pathol. 1997 Dec;17(6):403-5 [9526628.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1171-83 [9777979.001]
  • [Cites] Neurosurgery. 1998 Dec;43(6):1478-81; discussion 1481-2 [9848865.001]
  • [Cites] Am J Surg Pathol. 1999 May;23(5):502-10 [10328080.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2318-26 [15470710.001]
  • [Cites] Clin Neuropathol. 2004 Nov-Dec;23(6):262-70 [15584210.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):247-53 [15644783.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):231-4 [15549332.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):97-9 [15973544.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Oct;64(10):875-81 [16215459.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):281-6 [16389940.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Apr;32(2):217-20 [16599951.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Pathol Res Pract. 2006;202(10):745-50 [16884858.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1709-18 [18059228.001]
  • [Cites] Childs Nerv Syst. 1992 Aug;8(5):268-72 [1327526.001]
  • [Cites] Cancer. 1984 Jul 15;54(2):323-32 [6202392.001]
  • [Cites] J Neuropathol Exp Neurol. 1983 Nov;42(6):639-47 [6355400.001]
  • [Cites] Zentralbl Allg Pathol. 1985;130(1):31-43 [3984542.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1987 Dec;50(12):1619-24 [3325615.001]
  • [Cites] Arch Neurobiol (Madr). 1990 Jan-Feb;53(1):8-12 [2203326.001]
  • [Cites] Acta Neuropathol. 1988;76(5):528-31 [3188844.001]
  • [Cites] Pediatr Neurosci. 1987;13(4):188-95 [3136447.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):362-8 [10716149.001]
  • [Cites] Acta Neuropathol. 2000 Nov;100(5):575-9 [11045681.001]
  • [Cites] Hum Pathol. 2000 Nov;31(11):1435-8 [11112223.001]
  • [Cites] Acta Neuropathol. 2001 Apr;101(4):311-20 [11355302.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):82-8 [11453402.001]
  • [Cites] Acta Neuropathol. 2001 May;101(5):525-8 [11484825.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):582-91 [11979088.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1048-55 [12170092.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):505-12 [12657936.001]
  • [Cites] Rev Neurol (Paris). 2003 Jul;159(6-7 Pt 1):622-36 [12910070.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):506-8 [12915951.001]
  • [Cites] Neurosurgery. 2004 Mar;54(3):753-7; discussion 757-8 [15028154.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1445-54 [15368333.001]
  • [Cites] Acta Neuropathol. 1991;82(5):408-13 [1662856.001]
  • [ErratumIn] Acta Neuropathol. 2007 Nov;114(5):547
  • (PMID = 17618441.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 52
  • [Other-IDs] NLM/ PMC1929165
  •  go-up   go-down


2. Cerveny L, Pavek P, Malakova J, Staud F, Fendrich Z: Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia; 2006 Mar;47(3):461-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In epileptogenic brain tumors such as ganglioma, astrocytoma, anaplastic astrocytomas, or glioma multiforme, strong expression of BCRP in the microvasculature of the BBB was observed.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Anticonvulsants / pharmacokinetics. Blood-Brain Barrier / metabolism. Drug Resistance, Multiple / drug effects. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529607.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Anticonvulsants; 0 / Neoplasm Proteins
  •  go-up   go-down


3. Perry J, Chambers A, Spithoff K, Laperriere N: Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol; 2007 Oct;14(5):189-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliadel wafers in the treatment of malignant glioma: a systematic review.
  • QUESTION: What is the safety and efficacy of interstitial chemotherapy with carmustine-loaded polymers (Gliadel wafers: MGI Pharma, Bloomington, MN, U.S.A.) in the treatment of newly diagnosed or recurrent malignant glioma (that is, glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligoastrocytoma, and anaplastic oligodendroglioma)?
  • PERSPECTIVES: Malignant glioma is the most common type of primary brain tumour in adults.
  • RESULTS: Two RCTS that compared Gliadel to placebo in patients with newly diagnosed malignant glioma were obtained.
  • One RCT and one prospective cohort study were obtained that examined the role of Gliadel in patients with recurrent malignant glioma.
  • CONCLUSIONS: Gliadel is an option for selected patients with newly diagnosed malignant glioma where a near gross total resection is possible.
  • Gliadel is also an option for patients with surgically resectable recurrent malignant glioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3 [10414561.001]
  • [Cites] Surg Neurol. 2000 May;53(5):458-64 [10874145.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • (PMID = 17938702.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2002480
  • [Keywords] NOTNLM ; Gliadel / carmustine / glioblastoma / interstitial chemotherapy / malignant glioma / systematic review
  •  go-up   go-down


Advertisement
4. Kikuchi T, Kumabe T, Higano S, Watanabe M, Tominaga T: Minimum apparent diffusion coefficient for the differential diagnosis of ganglioglioma. Neurol Res; 2009 Dec;31(10):1102-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The minimum ADC (minADC) of each tumor was pre-operatively determined from several regions of interest.
  • The minADC of ganglioglioma was compared with that of low- or high-grade astrocytomas (astrocytoma, anaplastic astrocytoma and glioblastoma).
  • Tumor cellularity of gangliogliomas was compared with the minADC.
  • RESULTS: The mean minADC of the gangliogliomas (1.45 +/- 0.20 x 10(-3) mm(2)/s) was significantly higher than that of the low- or high-grade astrocytomas.
  • Tumor cellularity of ganglioglioma was inversely correlated with the minADC value.
  • DISCUSSION: The minADC value reflects in the low tumor cellularity of gangliogliomas and may provide a method for the differential diagnosis of ganglioglioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / pathology. Brain / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138470.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY: The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study. J Korean Neurosurg Soc; 2008 Oct;44(4):222-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study.
  • OBJECTIVE: Malignant gliomas are the most common primary cerebral neoplasms in adults.
  • Despite multimodality treatments, the prognosis for patients with malignant glioma remains poor.
  • We report for the first time preliminary results of the treatment with CCRT of newly diagnosed malignant gliomas in Korean people.
  • METHODS: Thirty-two patients over the age of 17 years with newly diagnosed and histologically confirmed high-grade gliomas (HGG), from June 2004 to August 2007 were the subjects of this study.
  • Pathologically, glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and gliomatosis cerebri had been diagnosed in eighteen, eight, four, and two patients, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2192-7 [18445844.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1371-80 [10780513.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1111-39, x [17964028.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):99-111 [17027279.001]
  • [Cites] Tumori. 2006 Jul-Aug;92(4):299-305 [17036520.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Cancer Radiother. 2005 Sep;9(5):322-31 [16095943.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Strahlenther Onkol. 2005 Mar;181(3):157-63 [15756519.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Can J Neurol Sci. 2007 Nov;34(4):402-10 [18062446.001]
  • (PMID = 19096681.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588321
  • [Keywords] NOTNLM ; Concomitant chemoradiotherapy / Glioblastoma / High-grade glioma / Temozolomide
  •  go-up   go-down


6. Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC: Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):380-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
  • PURPOSE: To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma.
  • Grade 3-4 toxicities were observed in 14 patients (48%).
  • The primary study endpoint was the 23-month (700-day) survival, the median survival of patients with anaplastic astrocytoma in a previous North Central Cancer Treatment Group trial.
  • CONCLUSION: Our results have demonstrated that pre-RT chemotherapy with this regimen is insufficiently active in patients with anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy


7. Chan DT, Poon WS, Chan YL, Ng HK: Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Hong Kong Med J; 2005 Dec;11(6):452-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
  • OBJECTIVE: To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma.
  • Histology reviewed by a neuropathologist was required to show anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed anaplastic oligoastrocytoma) or glioblastoma multiforme.
  • RESULTS: Twenty-two patients with recurrent malignant glioma were recruited between January 2001 and July 2004.
  • CONCLUSION. Preliminary results showed that temozolomide had an acceptable safety profile and anti-tumour activity in recurrent malignant glioma in local Chinese population.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340021.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


8. Guzman G, Oh S, Shukla D, Engelhard HH, Valyi-Nagy T: Expression of entry receptor nectin-1 of herpes simplex virus 1 and/or herpes simplex virus 2 in normal and neoplastic human nervous system tissues. Acta Virol; 2006;50(1):59-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oligodendroglioma, ependymoma, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma multiforme and meningothelial meningioma showed weak focal nectin-1-positivity.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599187.001).
  • [ISSN] 0001-723X
  • [Journal-full-title] Acta virologica
  • [ISO-abbreviation] Acta Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / nectins
  •  go-up   go-down


9. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K: Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol; 2010 Dec;100(3):449-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.
  • Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined.
  • We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV).
  • In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels.
  • PEA-15 expression level was inversely associated with WHO grade (P = 0.0006).
  • Next, we evaluated prognosis and PEA-15 expression levels in 43 patients with high-grade astrocytomas based on the following parameters: age, gender, WHO grade, surgical resection extent, MIB-1 labeling index (LI), and PEA-15 expression level.
  • Multivariable analyses revealed that high PEA-15 expression level displayed a significant correlation with longer overall survival (OS) in high-grade astrocytomas (P = 0.0024).
  • In conclusion, PEA-15 expression level was inversely associated with WHO grade and may serve as an important prognostic factor for high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Phosphoproteins / metabolism. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Health Statistics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] J Neurosci. 1999 Oct 1;19(19):8244-51 [10493725.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25020-5 [11976344.001]
  • [Cites] Radiother Oncol. 2007 Dec;85(3):371-8 [18035440.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7012-21 [16044159.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1155-66 [17700518.001]
  • [Cites] Mol Biol Cell. 2006 Dec;17(12):5141-52 [16987961.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(11):5005-15 [15143191.001]
  • [Cites] J Neurochem. 1998 Sep;71(3):1307-14 [9721757.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4511-21 [12808093.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1162-70 [11221847.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):729-35 [15916534.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1536-44 [17308092.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4409-15 [10442631.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2416-26 [18284607.001]
  • [Cites] Dev Cell. 2001 Aug;1(2):239-50 [11702783.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3552-61 [15917297.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9302-10 [19010903.001]
  • [Cites] Neuropathology. 2008 Oct;28(5):507-15 [18410277.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5911-20 [8449955.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12840-7 [14707138.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1491-9 [16452205.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1215-22 [17192900.001]
  • (PMID = 20455002.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / PEA15 protein, human; 0 / Phosphoproteins
  •  go-up   go-down


10. Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M, Iwata R, Higano S, Takanami K, Takai Y, Tominaga T: Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg; 2010 Aug;113(2):358-68
Hazardous Substances Data Bank. (L)-Methionine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Assessment of hypoxic conditions in brain tumors is important for predicting tumor aggressiveness and treatment response.
  • METHODS: The FRP-170 was injected and PET imaging was performed 2 hours later in 8 patients, including 3 with glioblastoma multiforme, 2 with oligodendroglioma, and 1 each with diffuse astrocytoma, anaplastic ganglioglioma, and recurrent anaplastic astrocytoma.
  • Tissues obtained at biopsy or radical resection were immunostained with hypoxia-inducible factor-1alpha (HIF-1alpha) antibody for the confirmation of hypoxia, except in the patient with recurrent anaplastic astrocytoma who was treated using Gamma Knife surgery.
  • RESULTS: The FRP-170 PET images showed marked uptake with upregulation of HIF-1alpha in the 3 glioblastomas multiforme, and moderate uptake in the recurrent anaplastic astrocytoma and one oligodendroglioma, but no uptake in the other tumors.
  • This new method can assess tumor hypoxia preoperatively and noninvasively.
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Biopsy. Carbon Isotopes. Cell Division. Female. Fluorodeoxyglucose F18. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Methionine. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Protons. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895196.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / FRP-170; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nitroimidazoles; 0 / Protons; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


11. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S: Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med; 2005 Dec;19(8):677-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by gliomas is greater than that by intact tissue, making methionine very useful for evaluation of tumor extent.
  • Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.
  • Tumor activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves.
  • The correlations between methionine uptake and tumor proliferation (tumor versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects.
  • The existence of significant correlations between T/N and Ki-67LI and between SUV and Ki-67LI was determined for astrocytic tumors.
  • Receiver operating characteristics (ROC) analysis of T/N and standardized uptake value (SUV) was performed for the group of astrocytic tumors.
  • Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031).
  • The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).
  • CONCLUSIONS: When analysis was confined to cases of astrocytic tumor, a correlation was noted between methionine accumulation and Ki-67LI.
  • For the astrocytic tumors, T/N ratio seemed to be more useful as a diagnostic indicator than SUV.
  • The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444993.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


12. Herndon J 2nd, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS: Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.
  • : e13016 Background: Recurrent malignant gliomas have a poor prognosis, with a median survival of 6-15 months, with grade 4 glioblastomas more aggressive than grade 3 anaplastic astrocytomas or oligodendrogliomas.
  • We report a phase I trial of vandetanib in combination with oral etoposide for recurrent malignant glioma.
  • METHODS: Patients with histologically documented recurrent grade 3 or grade 4 malignant glioma were eligible.
  • There was more hematologic toxicity than expected, with 3/6 of the patients enrolled at dose level 1 developing grade 4 neutropenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962830.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S: The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):2057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab.
  • Histologies included glioblastoma (GB), anaplastic astrocytomas (AA), anaplastic oligodendrogliomas (AO), anaplastic oligoastrocytomas (AOA), and low-grade astrocytomas.
  • It is unclear why the disparity among this subset of patients occurs, however, we hypothesize that this may once again highlight the distinct tumor biology among young glioma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lassman AB, Oligodendroglioma Study Group: Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors.
  • : 2014 Background: Treatment of anaplastic oligodendroglial tumors is controversial.
  • METHODS: We retrospectively identified adults with newly diagnosed anaplastic oligodendroglioma (AO) or oligo-astrocytoma (AOA) seen at 17 medical centers from 1981-2007 exclusive of phase III or bone marrow transplant trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Rudnick JD, Phuphanich S, Chu R, Mazer M, Wang H, Serrano N, Francisco M, Black KL, Wheeler C, Yu J: A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):2033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
  • : 2033 Background: Our prior immunotherapy trials demonstrated efficacy in generating a tumor specific immune response in malignant glioma and the potential for high tumor-specific toxicity and sustained tumoricidal activity.
  • METHODS: We exploited this synergistic effect to maintain a cytotoxic environment around the tumor milieu.
  • Patients with high-grade glioma were eligible after maximal resection with biodegradable carmustine (BCNU) wafer placement.
  • Screening leukapheresis is used to isolate mononuclear cells which are differentiated into dendritic cells, pulsed with tumor lysate, and then 3 intradermal vaccines are administered at 2-week intervals.
  • The histology included 3 newly diagnosed glioblastoma multiforme (GBM), 8 recurrent GBM, 2 newly diagnosed anaplastic astrocytoma (AA), and 2 recurrent AA.
  • Our preliminary data on 15 patients and 39 courses of Dendritic Cell vaccines demonstrate one grade 3 toxicity of fever/chest pain.
  • CONCLUSIONS: This phase I study demonstrates the safety, feasibility of dendritic cell vaccination with biodegradable carmustine (BCNU) wafers with one grade 3 AE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964627.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Franceschi E, Tosoni A, Ermani M, Spagnolli F, La Torre L, Galzio RJ, Pozzati E, Talacchi A, Benevento F, Brandes AA: Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas.
  • : e13003 Background: Chromosomes 1p/19q codeletion has been recognized as a prognostic and predictive factor in patients (pts) with grade 3 gliomas.
  • Non-codeleted (intact) anaplastic oligodendroglioma showed a survival comparable to that usually observed in pts with anaplastic astrocytomas; MGMT methylation status, moreover, has been found to be a prognostic factor in glioblastoma and anaplastic gliomas (AG).
  • Histology was anaplastic oligodendroglioma in 17 pts, anaplastic oligoastrocytoma in 20 pts, and anaplastic astrocytoma in 30 pts; all these pts were 1p19q intact and received surgery, RT, and CT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Abacioglu MU, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M: Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma.
  • : e13018 Background: The study was aimed to evaluate the efficacy of TMZ on a protracted dose-dense schedule after standard 5-day TMZ regimen in patients with progressive high-grade glioma.
  • METHODS: In this phase II prospective study, patients who had progression on standard 5-day TMZ for recurrence (group 1) or recurrence after concurrent radiotherapy+TMZ and ≥ 2 cycles of adjuvant TMZ (group 2) for high-grade glioma received TMZ 100 mg/m2× 21 q28 days until progression according to MacDonald's criteria.
  • The histopathology was glioblastoma in 18 and grade 3 glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma) in 7.
  • Out of 80 cycles received there was no anemia; 5 (6%) grade 1, 8 (10%) grade 2, 2 (3%) grade 3 leucopenia; 1 (1%) grade 1, 2 (3%) grade 2, 1 (1%) grade 3, 1 (1%) grade 4 thrombocytopenia; 9 (11%) grade 1, 7 (9%) grade 2, 32 (40%) grade 3, and 11 (14%) grade 4 lymphopenia.
  • Study was terminated in 2 patients (one with grade 4 thrombocytopenia and the other with grade 4 hepatic toxicity).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962826.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).
  • METHODS: Eligibility included: adult patients with stable or recurrent MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO]) previously treated with radiation therapy (RT) and with or without chemotherapy; interval of at least two weeks between prior RT, or four weeks between prior chemotherapy; Karnofsky ≥ 60%; and adequate hematologic, renal and liver function.
  • Dose-limiting toxicities were: deep venous thrombosis (1 grade 3); nausea and vomiting (1 grade 3); diarrhea (1 grade 3); elevated ALT (1 grade 3); elevated creatinine (1 grade 3); and fatigue (1 grade 3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Simonelli M, Banna G, Navarria P, Di Ieva A, Zucali P, De Vincenzo F, Gaetani P, Condorelli R, Rodriguez Y Baena R, Scorsetti M, Santoro A: Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas.
  • : e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.
  • Currently, the addition of chemotherapy to radiotherapy (RT) for newly diagnosed anaplastic gliomas is not sustained by available data.
  • We evaluated the addition of temozolomide (TMZ) to radiotherapy for newly diagnosed anaplastic gliomas in terms of tolerability, progression-free survival (PFS), and overall survival (OS).
  • METHODS: Since September 2004, following initial surgery, patients (pts) with histologically confirmed anaplastic glioma, Karnofsky Performance Status (KPS) ≥40, adequate organ function, no prior chemotherapy, were treated with RT to limited fields once daily at 2 Gy per fraction, 5 days a week, for a total of 60 Gy with concomitant TMZ (75 mg/m<sup>2</sup> for 7 days a week) followed by 6 cycles of maintenance TMZ at 200 mg/m<sup>2</sup> on days 1-5 every 28 days.
  • Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.
  • Frequent mild toxicities were grade 1-2 nausea/vomiting (17 pts-63%), and grade 1-2 asthenia (8 pts-30%).
  • CONCLUSIONS: The addition of temozolomide to radiation therapy for newly diagnosed anaplastic gliomas is well tolerated and seems active; efficacy needs confirmation in a randomized clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM: Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. J Clin Oncol; 2009 May 20;27(15_suppl):2042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.
  • Safety and efficacy of intracerebral inoculations of G207 to patients suffering from recurrent malignant gliomas have been demonstrated in previous clinical trials.
  • METHODS: In this phase I clinical trial, a total of 1 x 10<sup>9</sup> plaque forming units (pfu) G207 were administered by five stereotactic injections of 0.2 mL each into regions of recurrent malignant glioma defined by MRI, followed by focal radiation therapy 24 hours post injection.
  • Included patients suffered from inoperable pathologically proven recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) which was progressive despite radiotherapy or chemotherapy and failed external beam radiotherapy > 5 Gray prior to study enrolment.
  • The 2 patients with initial PR (1xGBM, 1xAA) were re-treated with G207/Irradiation at time point of tumor recurrence, showing PR one month after re-treatment again.
  • Within persistent areas of tumor, HSV staining was present by using a polyclonal antibody for HSV, indicating intratumoral G207 replication (proof of concept).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Tosoni A, Franceschi E, Ermani M, Bacci A, Volpin L, Lombardo L, Ravenna G, Pinna G, Poggi R, Brandes AA: MGMT methylation status as a prognostic factor in anaplastic astrocytomas. J Clin Oncol; 2009 May 20;27(15_suppl):2052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT methylation status as a prognostic factor in anaplastic astrocytomas.
  • However, further data on the epigenetic feature are needed before its role in rare diseases such as anaplastic astrocytomas (AA) can be established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964674.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H: Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol; 2008 Oct;15(10):2887-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
  • BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival.
  • We set out to characterize Gliadel-associated morbidity in our 10-year experience with Gliadel wafers for treatment of malignant glioma.
  • METHODS: We retrospectively reviewed records of 1013 patients undergoing craniotomy for resection of malignant brain astrocytoma (World Health Organization grade III/IV disease).
  • RESULTS: A total of 1013 craniotomies were performed for malignant brain astrocytoma.
  • A total of 288 (28%) received Gliadel wafer (250 glioblastoma multiforme (GBM), 38 anaplastic astrocytoma/anaplastic oligodendroglioma (AA/AO), 166 primary resection, 122 revision resection).
  • Patients in Gliadel versus non-Gliadel cohorts had similar incidences of perioperative surgical site infection (2.8% vs. 1.8%, P = .33), cerebrospinal fluid leak (2.8% vs. 1.8%, P = .33), meninigitis (.3% vs. .3%, P = 1.00), incisional wound healing difficulty (.7% vs. .4%, P = .63), symptomatic malignant edema (2.1% vs. 2.3%, P = 1.00), 3-month seizure incidence (14.6% vs. 15.7%, P = .65), deep-vein thrombosis (6.3% vs. 5.2%, P = .53), and pulmonary embolism (PE) (4.9% vs. 3.7%, P = .41).
  • CONCLUSION: In our experience, use of Gliadel wafer was not associated with an increase in perioperative morbidity after surgical treatment of malignant astrocytoma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636295.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biocompatible Materials; 0 / Decanoic Acids; 0 / Drug Carriers; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


23. Rao SA, Santosh V, Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol; 2010 Oct;23(10):1404-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.
  • Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).
  • Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.
  • We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.
  • More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.
  • The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).
  • Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. MicroRNAs / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711171.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


24. Khalatbari M, Borghei-Razavi H, Shayanfar N, Behzadi AH, Sepehrnia A: Collision tumor of meningioma and malignant astrocytoma. Pediatr Neurosurg; 2010;46(5):357-61
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of meningioma and malignant astrocytoma.
  • The pathology of tumors reported collision tumors composed of meningioma and malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389747.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S: p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol; 2010 Oct;27(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 abnormality and tumor invasion in patients with malignant astrocytoma.
  • Malignant astrocytomas are characterized by diffusely infiltrating nature, and the abnormality of p53 is a cytogenetic hallmark of astrocytic tumors.
  • To elucidate the relationship between p53 abnormality and invasiveness of the tumors, we studied mutation and protein expression of p53 in 48 consecutive patients with malignant astrocytoma (14 anaplastic astrocytomas and 34 glioblastoma multiformes).
  • The tumors were classified into three categories according to the features of magnetic resonance imaging, and 5, 7, and 36 tumors were classified into diffuse, multiple, and single type, respectively.
  • We then examined how these tumor types correlate with MIB-1 staining index, TP53 gene mutation, and p53 protein expression.
  • Furthermore, diffuse- and multiple-type tumors were significantly correlated with poor progression-free survival, whereas only multiple-type tumors were significantly correlated with poor overall survival.
  • As diffuse and multiple features on imaging modalities represent invasive characteristics of the tumors, p53 abnormalities may affect the invasive and aggressive nature of malignant astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Genes, p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA, Neoplasm / genetics. Female. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Mutation / genetics. Mutation / physiology. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Survival Analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046311.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


26. Khwaja FW, Duke-Cohan JS, Brat DJ, Van Meir EG: Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res; 2006 Nov 1;12(21):6331-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration.
  • The goal of our study was to find reliable markers that could be used for disease monitoring as well as to identify new targets for the therapeutic intervention for malignant astrocytoma (WHO grades 3 and 4).
  • EXPERIMENTAL DESIGN: We employed proteomic techniques to identify secreted proteins in the cerebrospinal fluid that were specific to patients with malignant astrocytoma.
  • RESULTS: Among 60 cerebrospinal fluid samples of patients with various central nervous system diseases, attractin was consistently found to be elevated in the samples of patients with malignant astrocytoma.
  • To independently validate these results, we examined attractin expression in a new set of 108 normal and tumoral brain tissue specimens and found elevated expression in 97% of malignant astrocytomas, with the highest levels in grade 4 tumors.
  • Using immunohistochemistry, we further showed that attractin is produced and secreted by the tumor cells.
  • Finally, we showed that cerebrospinal fluid from brain tumor patients induces glioma cell migration and that attractin is largely responsible for this promigratory activity.
  • CONCLUSIONS: Our results find attractin to be a reliable secreted marker for high-grade gliomas.
  • Additionally, our migration studies suggest that it may be an important mediator of tumor invasiveness, and thus, a potential target in future therapies.
  • [MeSH-major] Astrocytoma / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Cell Movement / physiology. Glioma / cerebrospinal fluid. Membrane Proteins / cerebrospinal fluid
  • [MeSH-minor] Blotting, Western. Electrophoresis, Gel, Two-Dimensional. Humans. Immunohistochemistry. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085642.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 86335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATRN protein, human; 0 / Membrane Proteins
  •  go-up   go-down


27. Ryu HH, Jung S, Sun HS, Jung TY, Jin SG, Jin YH, Kim IY, Jeong YI, Kang SS: Screening for motility-associated genes in malignant astrocytoma cell lines. J Neurooncol; 2007 Apr;82(2):125-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for motility-associated genes in malignant astrocytoma cell lines.
  • The most characteristic feature of a malignant astrocytoma is its early and extensive infiltration into adjacent parenchymal structures.
  • We focused on detecting the possible expression changes as the determining factors for malignant astrocytoma's motile ability.
  • These findings suggest that the genes identified may be important for determining high motility in astrocytoma cell lines.
  • These findings may help us understand the molecular invasion mechanism in astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cell Movement. Gene Expression Profiling
  • [MeSH-minor] Humans. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1996 Dec;2(12):1305-6 [8946822.001]
  • [Cites] Pol J Pathol. 2004;55(1):3-12 [15195701.001]
  • [Cites] Am J Hum Genet. 2003 Jul;73(1):34-48 [12802786.001]
  • [Cites] Nat Rev Neurosci. 2003 Sep;4(9):752-62 [12951567.001]
  • [Cites] Neurochem Res. 2003 Aug;28(8):1265-73 [12834267.001]
  • [Cites] EXS. 1995;74:157-79 [8527892.001]
  • [Cites] Biol Chem. 2001 May;382(5):743-51 [11517927.001]
  • [Cites] J Comp Neurol. 1990 Dec 1;302(1):100-9 [2086609.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):105-17 [11322830.001]
  • [Cites] Brain Res. 1995 Oct 30;697(1-2):179-86 [8593575.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Dec;34(12):1539-43 [12379276.001]
  • [Cites] FASEB J. 1994 Aug;8(11):814-22 [8070630.001]
  • [Cites] Brain Res. 1995 Oct 30;697(1-2):112-21 [8593567.001]
  • [Cites] Biochem Pharmacol. 1998 Dec 1;56(11):1489-92 [9827582.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2361-9 [9840536.001]
  • [Cites] Microsc Res Tech. 1998 Dec 1;43(5):369-78 [9858334.001]
  • [Cites] Cell Growth Differ. 1995 Nov;6(11):1375-80 [8562475.001]
  • [Cites] Ann Univ Mariae Curie Sklodowska Med. 2003;58(2):390-3 [15323224.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):585-96 [12125737.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Apr 17;209(2):760-7 [7733948.001]
  • [Cites] Biotechniques. 2004 Mar;36(3):424-6, 428, 430 passim [15038158.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47233-8 [11551918.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):129-41 [11322832.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):70-3 [9731535.001]
  • [Cites] J Neurosci. 1986 Nov;6(11):3103-11 [3021924.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4190-6 [11358844.001]
  • (PMID = 17048098.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K: Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res; 2008 Sep;14(3):293-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma.
  • The aim of the study was to analyze the expression of OPN in human astrocytomas and to correlate it with angiogenesis and patients' outcome.
  • Seventy-six human astrocytomas including eight pilocytic astrocytomas (grade I), 10 diffuse astrocytomas (grade II), 8 anaplastic astrocytomas (grade III) and 50 glioblastomas (grade IV) were immunohistochemically stained for OPN protein.
  • Astrocytomas were heterogeneous regarding the OPN expression.
  • Our results indicate the overexpression of OPN protein in astrocytoma cells and suggest the role of OPN in astrocytoma progression and angiogenesis.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Brain Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Osteopontin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Stroke. 1998 Aug;29(8):1698-706; discussion 1707 [9707214.001]
  • [Cites] J Surg Oncol. 2006 Sep 15;94(4):325-31 [16917865.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1967-73 [10864205.001]
  • [Cites] J Vet Med Sci. 2004 Oct;66(10):1307-10 [15528873.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4237-46 [10435636.001]
  • [Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):293-305 [8686754.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4820-8 [12183442.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]
  • [Cites] Brain Res. 2005 Apr 11;1041(1):95-101 [15804504.001]
  • [Cites] J Cell Biochem. 1994 Sep;56(1):48-51 [7528752.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):107-17 [12893437.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):807-12 [9615723.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2734-42 [10733576.001]
  • [Cites] J Cell Biol. 1998 May 18;141(4):1083-93 [9585425.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2166-76 [16208410.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):161-76 [11716068.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1198-205 [12606946.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5336-43 [12235004.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Jun;31(3):292-303 [15885066.001]
  • [Cites] Front Biosci. 1999 Feb 15;4:D188-99 [9989953.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):398-405 [17524506.001]
  • [Cites] Am J Pathol. 2006 May;168(5):1676-85 [16651633.001]
  • (PMID = 18493866.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


29. Parafiniuk D, Jezewski D, Nowacki P: [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review]. Ann Acad Med Stetin; 2010;56(2):45-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review].
  • Astrocytomas--neroepithelial originated tumors that belong to the big, differential group of tumors, which derive from astrocytic glial.
  • They include slow growing tumors such as fibillary astrocytoma or very malignant glioblastoma multiforme.
  • The case which is being presented is of a forty nine year old woman operated in July 1997 because of a protoplasmic astrocytoma II WHO in the left frontal lobe.
  • Due to this adverse event MRI was ordered and suspicion of tumor recurrence was put forward.
  • Histopathology identified anaplastic astrocytoma III WHO.
  • According to literature, the factors regarding remission time, tumor malignancy and therapeutic aim were analyzed.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Astrocytoma. Female. Frontal Lobe. Humans. Reoperation. Seizures / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21473001.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  •  go-up   go-down


30. Marsh J, Mukherjee P, Seyfried TN: Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr Metab (Lond); 2008 Nov 25;5:33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet.
  • BACKGROUND: Astrocytomas are largely dependent on glycolysis to satisfy their bioenergetic requirements for growth and survival.
  • Therapies that target glycolysis can potentially manage astrocytoma growth and progression.
  • Dietary restriction of the high fat/low carbohydrate ketogenic diet (KD-R) reduces glycolysis and is effective in managing experimental mouse and human astrocytomas.
  • The goal here was to determine if low doses of 2-DG could act synergistically with the KD-R to better manage growth of the CT-2A malignant mouse astrocytoma.
  • METHODS: The therapeutic effect of a KD-R supplemented with a low dose of 2-DG (25 mg/kg) was examined in adult C57BL/6J mice bearing the syngeneic CT-2A malignant astrocytoma grown orthotopically.
  • Mice were fed the standard unrestricted diet for the first 3 days after tumor implantation prior to their separation into one of four diet groups fed either a standard rodent diet in unrestricted amounts (SD-UR) or a KD-R with or without 2-DG for 10 days.
  • 2-DG was initiated 6 days after tumor implantation and was continued for 7 days.
  • RESULTS: Energy intake, body weights, and CT-2A tumor weights were similar in the SD-UR and the SD-UR+2-2DG mouse groups over the dietary treatment period (days 3-13).
  • Tumor weights were about 48% and 80% lower in the KD-R and in the KD-R+2-DG groups, respectively, than in the SD-UR group.
  • CONCLUSION: Astrocytoma growth was reduced more in the KD-R mouse group supplemented with 2-DG than in the mouse groups receiving either dietary restriction or 2-DG alone, indicating a synergistic interaction between the drug and the diet.
  • The results suggest that management of malignant astrocytoma with restricted ketogenic diets could be enhanced when combined with drugs that inhibit glycolysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7751-62 [19047102.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Jan;28(1):1-16 [17684514.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Nutr Metab (Lond). 2007;4:5 [17313687.001]
  • [Cites] Epilepsia. 2007 Jan;48(1):31-42 [17241206.001]
  • [Cites] Behav Pharmacol. 2006 Sep;17(5-6):431-9 [16940764.001]
  • [Cites] Life Sci. 2006 Feb 16;78(12):1392-9 [16111712.001]
  • [Cites] Nutr Metab (Lond). 2005 Oct 21;2:30 [16242042.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):7023-30 [16061689.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):507-14 [16044218.001]
  • [Cites] Neurosci Lett. 2005 Sep 16;385(3):210-4 [15975714.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):615-7 [15687318.001]
  • [Cites] J Natl Cancer Inst. 1960 Feb;24:267-81 [14414406.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] J Natl Cancer Inst. 1958 Sep;21(3):485-94 [13576102.001]
  • [Cites] Arch Neurol. 1998 Jul;55(7):922-8 [9678309.001]
  • [Cites] J Am Coll Nutr. 1995 Apr;14(2):202-8 [7790697.001]
  • [Cites] Mol Chem Neuropathol. 1992 Oct;17(2):147-67 [1418222.001]
  • [Cites] Cancer Res. 1992 Oct 15;52(20):5794-6 [1394204.001]
  • [Cites] J Neurochem. 1991 Mar;56(3):1007-11 [1671582.001]
  • [Cites] J Nutr. 1984 Nov;114(11):2097-106 [6491763.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5622-9 [15328205.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19 [14769489.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1375-82 [14520474.001]
  • [Cites] J Neurochem. 2003 Aug;86(3):529-37 [12859666.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3413-7 [12810678.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):805-12 [12232767.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1615-21 [12085212.001]
  • [Cites] J Lipid Res. 2008 Dec;49(12):2545-56 [18703489.001]
  • (PMID = 19032781.001).
  • [ISSN] 1743-7075
  • [Journal-full-title] Nutrition & metabolism
  • [ISO-abbreviation] Nutr Metab (Lond)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102135; United States / NINDS NIH HHS / NS / R01 NS055195; United States / NINDS NIH HHS / NS / R56 NS055195
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2607273
  •  go-up   go-down


31. Yoshida T, Niwa F, Kimura S, Nakagawa M: Anaplastic astrocytoma presenting as reversible posterior leukoencephalopathy syndrome. Neurologist; 2006 Nov;12(6):311-3
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma presenting as reversible posterior leukoencephalopathy syndrome.
  • We report a 60-year-old man with grade III astrocytoma, who presented with status epilepticus.
  • The initial MRI did not demonstrate typical findings of an astrocytoma but rather showed reversible posterior leukoencephalopathy syndrome (RPLS).
  • A brain tumor should be considered and the patient carefully followed by MRI, even if the MRI white matter lesion pattern suggests RPLS.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Diseases / diagnosis. Occipital Lobe / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122727.001).
  • [ISSN] 1074-7931
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C: Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci; 2008 Feb;15(2):114-21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
  • Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma.
  • We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant / methods. Dendritic Cells / immunology. Immunotherapy, Active / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083572.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / Cancer Vaccines; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


33. Nano R, Capelli E, Facoetti A, Benericetti E: Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res; 2009 Jul;29(7):2461-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunobiological and experimental aspects of malignant astrocytoma.
  • Starting from 1992, the goal of our studies was to obtain new biological data on malignant astrocytomas to better understand the basic biology of the tumour and these are reviewed here.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596914.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2
  • [Number-of-references] 51
  •  go-up   go-down


34. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol; 2008 Jan 10;26(2):271-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
  • PURPOSE: The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas.
  • The aim of these retrospective studies was to evaluate tumor vascularity and expression of components of the VEGF pathway and hypoxic responses as predictive markers for radiographic response and survival benefit from the bevacizumab and irinotecan therapy.
  • PATIENTS AND METHODS: In a phase II trial, 60 patients with recurrent malignant astrocytomas were treated with bevacizumab and irinotecan.
  • Tumor specimens collected at the time of diagnosis were available for further pathologic studies in 45 patients (75%).
  • RESULTS: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma.
  • CONCLUSION: In this patient cohort, tumor expression levels of VEGF, the molecular target of bevacizumab, were associated with radiographic response, and the upstream promoter of angiogenesis, hypoxia, determined survival outcome, as measured from treatment initiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Hypoxia. Male. Middle Aged. Neovascularization, Pathologic. Proportional Hazards Models. Radiography. Retrospective Studies. Survival Analysis. Treatment Outcome. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Nat Clin Pract Neurol. 2006 May;2(5):232-3 [16932555.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5260-4 [17000656.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6130-4 [14559790.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 18182667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS054276; United States / NCI NIH HHS / CA / R01 CA116659; United States / NCI NIH HHS / CA / CA116659; United States / NINDS NIH HHS / NS / K02 NS047409; United States / NINDS NIH HHS / NS / NS047409; United States / NINDS NIH HHS / NS / R01 NS054276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS508913; NLM/ PMC3930173
  •  go-up   go-down


35. Jayawardena S, Sooriabalan D, Indulkar S, Kim HH, Matin A, Maini A: Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. Am J Ther; 2006 Sep-Oct;13(5):458-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
  • Astrocytomas are central nervous system neoplasms, which are derived predominately from astrocytes.
  • On the basis of the histopathologic characteristics astrocytomas are graded from I to IV.
  • The cells that demonstrate the greatest degree of anaplasia are used to determine the histologic grade of the tumor.
  • The mean age of survival are approximately 10 years from the time of diagnosis for pilocystic astrocytomas (World Health Organization grade I), more than 5 years for patients with low-grade diffuse astrocytomas (WHO grade II), 2 to 5 years for those with anaplastic astrocytomas (WHO grade III), and less than 1 year for patients with glioblastoma (WHO grade IV).
  • The treatment is a combination of surgery, radiation, and chemotherapy depending of the grade of astrocytoma.
  • We present a case of 31-year-old man with grade III astrocytoma with subsequent chronic myelogenous leukemia treated with imatinib mesylate as part of his chronic myelogenous leukemia treatment failing to show recurrence of the astrocytoma 10 years after standard treatment for astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988542.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


36. Arai Y, Tsuchida T, Tanioka F, Sugimura H, Watanabe C, Hongo T, Tsutsui Y: Congenital anaplastic astrocytoma differentiated into pilocytic astrocytoma: an autopsy case. Neuropathology; 2008 Aug;28(4):433-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital anaplastic astrocytoma differentiated into pilocytic astrocytoma: an autopsy case.
  • We report an autopsy case of congenital astrocytoma and its histopathological changes during 5 years of the patient's development from birth to death.
  • At birth, a right exophthalmic tumor was observed, and MRI revealed that the tumor occupied the right orbital space and had also affected the suprasellar diencephalic structures.
  • The right orbital tumor, which was enucleated at 2 months of age, was a highly cellular tumor with moderate pleomorphism resembling anaplastic astrocytoma.
  • On the other hand, at autopsy, a brain tumor was found in the right diencephalic region with features of pilocytic astrocytoma, accompanied by leptomeningeal dissemination.
  • A biopsy specimen, which was obtained from the chiasmatic part of the tumor at 4 months of age, showed an intermediate appearance between the orbital tumor and the brain tumor obtained at autopsy.
  • Immunohistochemical examination confirmed that all three phases of the tumors showed an astrocytic lineage, and the Ki-67 labeling index decreased rapidly after 2 months of age.
  • We believe that this congenital anaplastic astrocytoma differentiated into a pilocytic astrocytoma during the 5 years of the patient's development.
  • The transformation of the congenital astrocytoma from anaplastic to pilocytic forms can be attributed to the nature of the tumor, namely postmitotic neoplastic cells are characterized by their ability to undergo self-differentiation, along with the organotropism of the developing brain.
  • [MeSH-major] Astrocytoma / congenital. Astrocytoma / pathology. Brain Neoplasms / congenital. Brain Neoplasms / pathology


37. Jang SY, Kong MH, Song KY, Frazee JG: Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult. J Korean Neurosurg Soc; 2009 Jun;45(6):381-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial Metastases of Cervical Intramedullary Low-Grade Astrocytoma without Malignant Transformation in Adult.
  • The first case of intracranial metastases of a cervical intramedullary low-grade astrocytoma without malignant transformation in adult is presented in this report.
  • Seven years ago, a 45 year-old male patient underwent biopsy to confirm pathologic characteristics and received craniocervical radiation and chemotherapy for a grade II astrocytoma in the cervical spinal cord.
  • The tumor at the cervical and brain lesions was classified as an astrocytoma (WHO grade II).
  • When a patient with low-grade astrocytoma in the spinal cord has new cranial symptoms after surgery, radiaton, and chemotherapy, the possibility of its metastasis should be suspected because it can spread to the intracranial cavity even without malignant transformation as shown in this case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Dec;50(3):239-43 [11263503.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):374-7 [11437586.001]
  • [Cites] Spinal Cord. 2006 Dec;44(12):740-5 [16670687.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] Neurosurgery. 2005;56(1):191 [15617606.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):560-2 [9324344.001]
  • [Cites] Neurosurgery. 1997 Jan;40(1):141-51 [8971836.001]
  • [Cites] J Neurooncol. 1995;25(3):245-50 [8592175.001]
  • [Cites] J Neurosurg. 1995 Sep;83(3):480-5 [7666226.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] J Neurooncol. 1994;18(1):49-52 [8057134.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):355-9 [1506881.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] Br J Surg. 1975 Feb;62(2):92-5 [1115920.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):114-8 [14762681.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):554-61 [12879473.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] J Neurosurg. 2006 Dec;105(6 Suppl):508-14 [17184088.001]
  • (PMID = 19609424.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2711238
  • [Keywords] NOTNLM ; Astrocytoma / Cranial metastases / Intramedullary / Spinal cord tumor
  •  go-up   go-down


38. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.
  • One year later, the anaplastic astrocytoma was found to have transformed into a glioblastoma multiforme.
  • Fluorescence in situ hybridization analysis and immunohistochemical examinations detected deletions of the lp36 and 19q13 loci, and nuclear accumulation of TP53 protein in the anaplastic oligodendroglioma but not in the glioblastoma multiforme.
  • These findings suggest that central neurocytoma or progenitor cells have the potential for oligodendrocytic and astrocytic transformation with different genetic aberrations.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Time Factors


39. Yue WY, Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem; 2005 Aug;53(8):997-1002
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does vasculogenic mimicry exist in astrocytoma?
  • Vasculogenic mimicry (VM) has been observed in melanoma and in some nonmelanoma tumor types.
  • It is unknown whether a similar VM phenomenon exists in astrocytoma.
  • The present study was to examine 45 astrocytomas (including World Health Organization grade II 15 cases, grade III 15 cases, and grade IV 15 cases) by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining to see if VM existing in these tumors.
  • The results demonstrated that endothelium-lined vessels dominated the tumor microvasculature and stained positively for PAS, laminin, and endothelial marker.
  • PAS-positive pattern of VM was found in two grade IV astrocytomas.
  • Channels stained positively for PAS, laminin, and negatively for CD34 of the VM entrapped in the tumor tissue.
  • Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.
  • It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.
  • The present results suggest that VM phenomenon exists in some malignant astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD34 / metabolism. Biomarkers / metabolism. Coloring Agents. Endothelium, Vascular / metabolism. Humans. Microcirculation. Neoplasm Staging. Periodic Acid. Schiff Bases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923371.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid
  •  go-up   go-down


40. Malhan P, Husain N, Bhalla S, Gupta RK, Husain M: Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.
  • Histological classification and grading are prime procedures in the management of patients with astrocytoma, providing vital data for therapeutic decision making and prognostication.
  • However, it has limitations in assessing biological tumor behavior.
  • This study was carried out to compare proliferative indices using proliferating cell nuclear antigen (PCNA), extent of p53 expression and micro vessel morphometric parameters in patients with low grade and anaplastic astrocytoma.
  • Twenty-five patients, each of grade II and grade III astrocytoma were evaluated using monoclonal antibodies to PCNA, p53 protein and factor VIII related antigen.
  • Patients with grade III astrocytoma had higher PCNA and p53 labeling indices as compared with grade II astrocytoma (29.14 plus/minus 9.87% vs. 16.84 plus/minus 6.57%, p 0.001; 18.18 plus/minus 6.14% vs. 6.14 plus/minus 7.23%, p 0.001, respectively).
  • Micro vessel percentage area of patients with grade III astrocytoma was also (4.26 plus/minus 3.70 vs. 1.05 plus/minus 0.56, p 0.001), higher along with other micro vessel morphometric parameters.
  • Discordance between histology and one or more IHC parameters was seen in 5/25 (20%) of patients with grade III astrocytoma and 9/25 (36%) of patients with grade II disease.
  • Increased proliferative fraction, genetic alterations and neovascularization mark biological aggressiveness in astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / pathology. Neovascularization, Pathologic. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090216.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


41. Reardon DA, Rich JN, Friedman HS, Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol; 2006 Mar 10;24(8):1253-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the treatment of malignant astrocytoma.
  • Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms.
  • Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress.
  • The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.
  • [MeSH-major] Astrocytoma / therapy. Central Nervous System Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525180.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 209
  •  go-up   go-down


42. Guan X, Lai S, Lackey J, Shi J, Techavipoo U, Moulding HD, Flanders AE, Andrews DW: Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging. J Magn Reson Imaging; 2008 Dec;28(6):1322-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging.
  • PURPOSE: To seek to distinguish and visualize the different magnetic resonance imaging (MRI) growth patterns among malignant gliomas utilizing visually enhanced diffusion tensor imaging (DTI).
  • MATERIALS AND METHODS: Nineteen consecutive patients undergoing image-guided resection of a newly diagnosed malignant glioma underwent add-on acquisition of DTI data based on an Institutional Review Board (IRB)-approved imaging protocol during preoperative MRI scans for routine intraoperative image guidance.
  • Tumor growth patterns were assigned to expansive or mixed/infiltrative classes as described in the companion article (24).
  • Infiltrating tumors were WHO Grade IV astrocytomas and all expansive tumors were either WHO Grade III astrocytomas or WHO Grade II astrocytomas.
  • DTI-based white matter tractography was conducted and the DTI data were fused with anatomical images using an in-house software package we developed to enhance the visualization of the tumor/fiber interface.
  • RESULTS: Out of the 19 tumor patients studied, 11 had infiltrative tumors and the other 8 had expansive tumors.
  • While less clear with 2D axial diffusion color maps, visually enhanced 3D reconstructions of the tumor/fiber interface successfully corroborated distinctive growth patterns.
  • This was particularly evident when viewed in 3D video loops of each tumor/fiber interface.
  • CONCLUSION: We have successfully developed software that visually enhances the anatomic details of the tumor/fiber interface in patients with anaplastic astrocytomas.
  • These data support the existence of a subgroup of patients within the WHO Grade III classification with expansive tumors and a significantly better prognosis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Processing, Computer-Assisted
  • [MeSH-minor] Adult. Aged. Female. Humans. Imaging, Three-Dimensional. Magnetic Resonance Imaging, Interventional. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025901.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Stupp R, Reni M, Gatta G, Mazza E, Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol; 2007 Jul;63(1):72-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma in adults.
  • Anaplastic astrocytoma is an uncommon disease in the adult population.
  • Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.
  • In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for anaplastic astrocytoma .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478095.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 69
  •  go-up   go-down


44. Azad A, Deb S, Cher L: Primary anaplastic pilocytic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1704-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic pilocytic astrocytoma.
  • We report two adult patients with pilocytic astrocytomas with anaplastic features at initial diagnosis.
  • Pilocytic astrocytomas are low-grade astrocytomas that occur rarely in adults.
  • Initial presentation of a pilocytic astrocytoma with anaplastic features is particularly uncommon and making a definitive diagnosis of pilocytic astrocytoma with anaplastic features can be challenging.
  • It is critical to differentiate glioblastoma (World Health Organization [WHO] grade 4) and pilocytic astrocytoma with anaplastic features (WHO grade 3) from pilocytic astrocytoma (WHO grade 1) as there are significant therapeutic and prognostic implications.
  • Improved therapeutic strategies are required for pilocytic astrocytomas with anaplastic features.
  • [MeSH-major] Anaplasia / complications. Astrocytoma / complications. Brain Neoplasms / complications

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815416.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


45. Fernandez A, Karavitaki N, Ansorge O, Fazal-Sanderson V, Wass JA: Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary; 2008;11(3):325-30
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
  • Insulin-like growth factor type I (IGF-I) is an important promoter in the tumorigenesis of several extracranial and intracranial neoplasms.
  • In astrocytic-cell tumors, the role of autocrine and paracrine IGF-I expression in enhancing tumoral progression is well established.
  • However, the influence of systemic IGF-I levels on the clinical behavior of astrocytic neoplasms remains an open subject of research.
  • We report the case of a 28-year-old man who presented simultaneously with acromegaly and an anaplastic astrocytoma, which had rapidly progressed from a low-grade astrocytoma.
  • The coexistence of systemic IGF-I hypersecretion with a quick progression in the histopathological grade of the astrocytoma raises the compelling question of whether the clinical behavior of the astrocytic tumor was influenced by the acromegalic status.
  • The role of IGF-I signaling in the pathogenesis of astrocytic-cell tumors and the experience with therapeutic strategies addressing this pathway in astrocytomas are also discussed.
  • [MeSH-major] Acromegaly / complications. Astrocytoma / complications. Brain Neoplasms / complications
  • [MeSH-minor] Adult. Cranial Irradiation. Craniotomy. Disease Progression. Ergolines / therapeutic use. Humans. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Neoplasm Staging. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Treatment Outcome. Up-Regulation

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Horm Metab Res. 1999 Feb-Mar;31(2-3):114-9 [10226790.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5107-12 [1717138.001]
  • [Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):31-5 [9210051.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):377-92 [14585082.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2218-22 [8174129.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):315-25 [9440028.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]
  • [Cites] BMC Cancer. 2002 May 31;2:15 [12057025.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):109-19 [11550306.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Dec;55(6):731-3 [11895213.001]
  • [Cites] Growth Horm IGF Res. 2001 Apr;11(2):84-91 [11472074.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):199-209 [2164527.001]
  • [Cites] Endocr Rev. 2005 Dec;26(7):916-43 [16131630.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jan;63(1):13-9 [14748557.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1025-33 [10353735.001]
  • [Cites] Exp Cell Res. 1988 Jun;176(2):336-43 [2837402.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4444-9 [11134091.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5758-64 [2889527.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]
  • [Cites] Neurosurgery. 1996 Dec;39(6):1243-5; discussion 1245-6 [8938782.001]
  • [Cites] Neurobiol Dis. 2000 Dec;7(6 Pt B):657-65 [11114263.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):115-22 [11947942.001]
  • (PMID = 18000757.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; LL60K9J05T / cabergoline
  •  go-up   go-down


46. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J: Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol; 2007;377:203-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis.
  • Astrocytoma is graded as pilocytic (WHO grade I), diffuse (WHO grade II), anaplastic (WHO grade III), and glioblastoma multiforme (WHO grade IV).
  • The progression from low- to high-grade astrocytoma is associated with distinct molecular changes that vary with patient age, yet the prognosis of high-grade tumors in children and adults is equally dismal.
  • Whether specific gene expression changes are consistently associated with all high-grade astrocytomas, independent of patient age, is not known.
  • To address this question, we reanalyzed the microarray datasets comprising astrocytomas from children and adults, respectively.
  • We identified nine genes consistently dysregulated in high-grade tumors, using four novel tests for identifying differentially expressed genes.
  • Four genes encoding ribosomal proteins (RPS2, RPS8, RPS18, RPL37A) were upregulated, and five genes (APOD, SORL1, SPOCK2, PRSS11, ID3) were downregulated in high-grade by all tests.
  • Expression results were validated using a third astrocytoma dataset.
  • APOD, the most differentially expressed gene, has been shown to inhibit tumor cell and vascular smooth muscle cell proliferation.
  • This suggests that dysregulation of APOD may be critical for malignant astrocytoma formation, and thus a possible novel universal target for therapeutic intervention.
  • Further investigation is needed to evaluate the role of APOD, as well as the other genes identified, in malignant astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adult. Child. Chromosomes, Human. Cluster Analysis. Data Interpretation, Statistical. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Models, Genetic. Neoplasm Recurrence, Local. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634619.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 49
  •  go-up   go-down


47. Llaguno SA, Chen J, Kwon CH, Parada LF: Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma. Cold Spring Harb Symp Quant Biol; 2008;73:421-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma.
  • Malignant astrocytomas are highly invasive brain tumors that portend poor prognosis and dismal survival.
  • We previously reported tumor suppressor mouse models based on conditional inactivation of human astrocytoma-relevant genes p53, Nf1, and Pten.
  • These mice develop, with full penetrance, varying grades of astrocytic malignancy that recapitulate the human condition histologically and molecularly.
  • Our studies indicate a central role for neural stem cells and stem-cell-like cancer cells in tumor initiation and progression.
  • These mouse models thus represent powerful tools for investigating various aspects of tumor development that otherwise cannot be explored in humans.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology. Neurons / pathology
  • [MeSH-minor] Animals. Disease Models, Animal. Genes, Tumor Suppressor. Humans. Mice. Models, Neurological. Mutation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022744.001).
  • [ISSN] 1943-4456
  • [Journal-full-title] Cold Spring Harbor symposia on quantitative biology
  • [ISO-abbreviation] Cold Spring Harb. Symp. Quant. Biol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P50NS05260602
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


48. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology


49. Kinjo S, Yokoo H, Hirato J, Nakazato Y: Anaplastic astrocytoma with eosinophilic granular cells. Neuropathology; 2007 Oct;27(5):457-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma with eosinophilic granular cells.
  • On magnetic resonance imaging, a contrast-enhanced tumor in the left frontal lobe with perifocal edema was noted.
  • Thus, the tumor was histologically diagnosed as anaplastic astrocytoma.
  • The MIB-1 labeling index of the highest area of the tumor was 22%, while that of granular cells was 2.1%.
  • Such structures are relatively common in oligodendroglial tumors; however, they are extremely rare in astrocytic tumors.
  • The present case should also be discriminated from granular cell astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


50. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2006 Jan 1;106(1):172-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS).
  • Time to tumor progression ranged from 2-19 months (median, 4 mos; 95% CI, 2-6 mos).
  • CONCLUSIONS: CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Anaplasia. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323194.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


51. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 2 grade 3), leukopenia (7; 1 grade 3), deep vein thrombosis (5; 2 grade 3), hypertension (5; 1 grade 3), anemia (4; 0 grade 3) and wound dehiscence (1; 1 grade 3).
  • Time to tumor progression ranged from 1 to 20 months (median: 7).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):253-8 [15279718.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Stat Med. 1991 May;10(5):749-55 [2068428.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):3-8 [1572829.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):593-7 [1429080.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


52. Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ: Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2008 May 1;112(9):2038-45
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS).
  • The median time to tumor progression was 4.1 month.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


53. Brandes AA, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, Reni M, Rotilio A, Sotti G, Ermani M: Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol; 2006 Jul;8(3):253-60
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.
  • We compared survival in patients with anaplastic astrocytoma (AA) treated with adjuvant procarbazine, lomustine, and vincristine (PCV) with survival in patients treated with temozolomide.
  • The following prognostic factors were taken into account: patient age, extent of resection, performance status, presence of contrast enhancement in presurgical imaging, and type of adjuvant treatment.
  • Type of adjuvant chemotherapy was not a significant factor, either for progression-free survival or for overall survival.
  • [MeSH-major] Adjuvants, Pharmaceutic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Astrocytoma / drug therapy. Astrocytoma / mortality. Dacarbazine / analogs & derivatives

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2004 Oct;31(5):618-34 [15497115.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1109-15 [10613302.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):501-5 [11870527.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):981-90 [12631596.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • (PMID = 16723632.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; PCV protocol
  • [Other-IDs] NLM/ PMC1871946
  •  go-up   go-down


54. Khongkhatithum C, Visudtibhan A, Chiemchanya S, Visudhiphan P, Sanvivad P, Larbcharoensub N, Phudhicharoenrat S: Multicentric anaplastic astrocytoma in a child. J Clin Neurosci; 2007 Feb;14(2):176-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric anaplastic astrocytoma in a child.
  • We report a rare case of anaplastic astrocytoma with multicentric central nervous system lesions in a 10-year-old girl presenting with a 1-month history of progressive headache and paraparesis.
  • Neurological examination upon admission revealed papilloedema of both eyes and grade 2/5 weakness of both legs.
  • The histological diagnosis was anaplastic astrocytoma based on the WHO classification.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17161293.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


55. Jeong SM, Chung YG, Lee JB, Shin IY: Intracranial dissemination from spinal cord anaplastic astrocytoma. J Korean Neurosurg Soc; 2010 Jan;47(1):68-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial dissemination from spinal cord anaplastic astrocytoma.
  • We report a case of intracranial dissemination developing approximately 4 months after partial removal of a spinal cord anplastic astrocytoma in a 22-year-old male.
  • The tumor was partially removed.
  • The final histologic diagnosis was anaplastic astrocytoma.
  • He underwent computed tomography-guided stereotactic biopsy and histological appearance was consistent with anaplastic astrocytoma.
  • The clinical course indicates that the tumor originated in the spinal cord and extended into the subarachnoid space, first the spinal canal and later intracranial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathology. 2006 Dec;26(6):519-27 [17203587.001]
  • [Cites] Pathol Oncol Res. 2006;12(3):143-7 [16998593.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):211-6 [16552620.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] Rinsho Hoshasen. 1989 Feb;34(2):249-52 [2754823.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):50-4 [2909688.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • (PMID = 20157383.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2817520
  • [Keywords] NOTNLM ; Anaplastic astrocytoma / Intracranial dissemination / Spinal cord
  •  go-up   go-down


56. Tanaka K, Sasayama T, Kawamura A, Kondoh T, Kanomata N, Kohmura E: Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion. Neurol Med Chir (Tokyo); 2006 Apr;46(4):198-201
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion.
  • A 30-year-old man presented with a supratentorial malignant glioma manifesting as isolated progressive left oculomotor nerve paresis.
  • Computed tomography and magnetic resonance imaging showed an intra-axial tumor in the left temporal lobe, extending to the basal and prepontine cisterns, and compressing the brainstem.
  • The tumor was removed subtotally.
  • The histological diagnosis was anaplastic astrocytoma.
  • Malignant glioma with exophytic growth in the temporal lobe should be considered in the differential diagnosis of isolated oculomotor nerve paresis.
  • [MeSH-major] Astrocytoma / complications. Oculomotor Nerve Diseases / etiology. Supratentorial Neoplasms / complications. Temporal Lobe
  • [MeSH-minor] Adult. Astrocytes / pathology. Biomarkers, Tumor / analysis. Brain Stem / pathology. Cerebral Arteries / pathology. Cisterna Magna / pathology. Dominance, Cerebral / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Neuronavigation. Oculomotor Nerve / pathology. Oculomotor Nerve / surgery. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636512.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Brehar FM, Ciurea AV, Zarnescu O, Bleotu C, Gorgan RM, Dragu D, Matei L: Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells. Chirurgia (Bucur); 2010 Sep-Oct;105(5):685-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells.
  • OBJECTIVE: The number of evidences regarding the role of tumor stem cells (TSC) in the initiation and progression of high-grade astrocytomas became more and more numerous in the last years.
  • This issue has been intensively tested in glioblastoma, but little attention has been paid for anaplastic astrocytoma.
  • The main objective of this paper was to study the morphological characteristics of the xenografts developed from glioblastoma and anaplastic astrocytoma derived cancer stem cells.
  • METHODS: The authors of this study successfully isolated and partial characterized primary cultures of glioblastoma and anaplastic astrocytoma derived TSC.
  • RESULTS: The tumor xenografts which have been established in nude mice using TSC had different characteristics when compared with U87 xenografts previously developed by our group, and depend of the origin type of the tumors (glioblastoma versus anaplastic astrocytoma).
  • The diffuse growing pattern and cells infiltration have been more pronounced in both anaplastic astrocytoma and glioblastoma derived TSC xenografts compared with U87 line xenografts.
  • CONCLUSION: Our results support the hypothesis regarding the role of TSC in the infiltration process of glioblastoma and anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplastic Stem Cells / pathology. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141095.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


58. Gupta B, Raina J: Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma. Indian J Ophthalmol; 2007 Nov-Dec;55(6):458-60
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma.
  • A case of spontaneous, painless partial III (pupil-sparing) and IV fascicular nerve paresis as the first presentation of anaplastic astrocytoma is reported.
  • [MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Oculomotor Nerve Diseases / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiologe. 1999 Oct;39(10):821-7 [10550380.001]
  • [Cites] Acta Neurochir (Wien). 1979;49(1-2):35-45 [230705.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):946-9 [16326274.001]
  • [Cites] Neurol Neurochir Pol. 1983 Jul-Aug;17(4):471-5 [6646330.001]
  • [Cites] Neurosurgery. 1982 Apr;10(4):437-44 [7099393.001]
  • (PMID = 17951905.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2635986
  •  go-up   go-down


59. Hope AJ, Mansur DB, Tu PH, Simpson JR: Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma. Childs Nerv Syst; 2006 Sep;22(9):1201-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.
  • INTRODUCTION: Malignant brain tumors have been reported to occur after childhood irradiation more frequently than in the nonirradiated population.
  • DISCUSSION: In this study, we report the case of a 15-year-old boy treated for medulloblastoma with surgery and craniospinal radiotherapy, who developed a meningioma 18 years after initial treatment and subsequently an anaplastic astrocytoma 23 years after primary treatment.
  • The patient is currently alive but with recurrent astrocytoma after a complete remission on temozolomide monotherapy.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):469-74 [2536806.001]
  • [Cites] Ann Neurol. 1978 Oct;4(4):319-21 [727737.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] Childs Nerv Syst. 2004 Apr;20(4):243-6 [14704813.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Lancet. 1997 May 10;349(9062):1369 [9149706.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Jan;16(1):97-101 [12585346.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Clin Neuropathol. 1994 Sep-Oct;13(5):281-5 [7805312.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):622-7 [632887.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(7):697-700 [11534690.001]
  • [Cites] J Neuroradiol. 1983;10 (1):43-9 [6864263.001]
  • [Cites] Neurology. 1981 May;31(5):616-9 [7194977.001]
  • [Cites] Neurosurgery. 1980 May;6(5):546-51 [6251397.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Mar;100(1):56-9 [9637208.001]
  • [Cites] Can J Neurol Sci. 1984 Nov;11(4):475-8 [6518432.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]
  • [Cites] Eur J Paediatr Neurol. 1999;3(4):177-80 [10476368.001]
  • [Cites] Can J Neurol Sci. 1992 Nov;19(4):498-503 [1330262.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):445-9 [682008.001]
  • [Cites] Am J Public Health Nations Health. 1966 Dec;56(12):2114-20 [5334312.001]
  • [Cites] Cancer. 1979 Jan;43(1):129-36 [104784.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]
  • (PMID = 16570196.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


60. Anselmo NP, Rey JA, Almeida LO, Custódio AC, Almeida JR, Clara CA, Santos MJ, Casartelli C: Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. Genet Mol Res; 2009;8(4):1257-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.
  • Disruption or loss of tumor suppressor gene TP53 is implicated in the development or progression of almost all different types of human malignancies.
  • Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma.
  • The mutation found at exon 6 of the gene TP53 could be associated with the rapid tumoral progression found in this case, since the mutated p53 may inactivate the wild-type p53 and the p73alpha protein, which was conserved here, leading to an increase in cellular instability.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876867.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


61. Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D: Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol; 2005 Dec;181(12):768-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT).
  • PURPOSE: To assess the effect of reirradiation in recurrent WHO grade III astrocytomas.
  • PATIENTS AND METHODS: From January 1995 to July 2003, 40 patients with grade III gliomas were treated with fractionated stereotactic reirradiation at the time point of recurrence.
  • No toxicities > CTC grade 2 developed.
  • CONCLUSION: Fractionated stereotactic radiotherapy is well tolerated and effective in patients with recurrent grade III astrocytomas.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / surgery. Brain Neoplasms / mortality. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Radiosurgery / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362786.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA: Prognostic factors for anaplastic astrocytomas. J Neurooncol; 2007 Feb;81(3):295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for anaplastic astrocytomas.
  • Anaplastic astrocytomas (WHO grade III) constitute about 10% of all gliomas.
  • Definitive data on predictive and prognostic factors are lacking for these neoplasms that are considered the most enigmatic entity among the whole spectrum of astrocytic tumors because of their unclear biologic behavior and variable clinical outcome.
  • Currently, only few factors have been identified as useful for prognosis of anaplastic astrocytoma: age and Karnofsky Performance Status.
  • Potential prognostic biomarkers concern tumor suppressor genes on chromosome 9q that are involved in the RB1 pathway; PTEN, the PI3k/Akt/p70s6k cascade, survivin gene, Formylpeptide receptor, minichromosome maintenance protein 3 and genes on chromosome 7.
  • The state of the art pictured here underlie the recent interest on gene expression profile to identify aberrations useful to understand the biologic behavior of astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):213-6 [16365177.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):85-9 [15690121.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10 (15):4933-8 [15297393.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):496-501 [1851971.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4694-700 [9788624.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1167-77 [15759318.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] CA Cancer J Clin. 1990 Jan-Feb;40(1):9-26 [2104569.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jan;55(1):81-7 [8558174.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1260-7 [8651304.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):319-31 [10931365.001]
  • [Cites] Neuroradiology. 1997 May;39(5):348-50 [9189880.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Neurosurgery. 2004 Feb;54(2):349-57; discussion 357 [14744281.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Oncogene. 1995 Jun 1;10(11):2243-6 [7784070.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jun;13(2):86-93 [7542911.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):823-35 [15928303.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):249-58 [15671553.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):203-15 [12187956.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):195-206 [9523194.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):983-94 [8806688.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2775-83 [16284993.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):275-83 [15332332.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • (PMID = 17001519.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 55
  •  go-up   go-down


63. Ooba H, Abe T, Kamida T, Anan M, Momii Y, Tokuuye K, Fujiki M: Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1641-3
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • This report presents a 70-year-old male who presented with a rare malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • To our knowledge, malignant fibrous histiocytosis caused by proton therapy has not been reported, therefore the clinical features of this complication are described and previous cases are reviewed.
  • [MeSH-minor] Aged. Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766005.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


64. Fountaine T, Lind CR, Law AJ: Primary glioblastomas and anaplastic astrocytoma in a glioma family. J Clin Neurosci; 2006 May;13(4):497-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary glioblastomas and anaplastic astrocytoma in a glioma family.
  • Analysis of the patient's family tree revealed that out of seven children, he had a living son with anaplastic astrocytoma, a daughter who had died with a glioblastoma, and a son who had died with a histologically undiagnosed intrinsic brain tumour.
  • In view of what is known about the genetics of familial glioma, it is interesting to note the clinical evidence of both 'primary' glioblastoma and anaplastic astrocytoma in the same kindred.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Family Health. Glioblastoma / genetics

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678736.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


65. Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. World J Surg Oncol; 2007;5:89

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.
  • BACKGROUND: Malignant gliomas recur even after extensive surgery and chemo-radiotherapy.
  • Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.
  • After 6 cycles, the tumor became refractory to TMZ, and the patient was treated with interferon-beta at 3 x 106 international units/body, followed by 5 consecutive days of 200 mg/m2 TMZ in cycles of 28 days.
  • After the second cycle the tumor decreased in size by 50% (PR).
  • The tumor showed further shrinkage after 8 months and the patient's KPS improved from 70% to 100%.
  • The immunohistochemical study of the initial tumor specimen confirmed positive MGMT protein expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3354-60 [10955823.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):613-24 [11290467.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Mar;41(3):115-9; discussion 119-20 [11372553.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):175-81 [11995819.001]
  • [Cites] J Neurosurg. 2003 Dec;99(6):1047-52 [14705733.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7573-9 [16140920.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Sep;33(9):1279-85 [16969025.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1117-21 [17016602.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1155-60 [17024124.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1253-60 [17089046.001]
  • [Cites] J Interferon Res. 1990 Apr;10(2):141-51 [2140395.001]
  • [Cites] J Interferon Res. 1987 Jun;7(3):301-11 [3497213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4562-6 [7753843.001]
  • [Cites] Neurol Res. 2000 Dec;22(8):802-8 [11149242.001]
  • (PMID = 17683572.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1976115
  •  go-up   go-down


66. Gibson CJ, Parry NM, Jakowski RM, Eshar D: Anaplastic astrocytoma in the spinal cord of an African pygmy hedgehog (Atelerix albiventris). Vet Pathol; 2008 Nov;45(6):934-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma in the spinal cord of an African pygmy hedgehog (Atelerix albiventris).
  • These regions were completely effaced by a moderately cellular infiltration of highly pleomorphic polygonal to spindle shaped cells, mineralization, and necrosis, which were most consistent with anaplastic astrocytoma.
  • A diagnosis of anaplastic astrocytoma was confirmed using immunohistochemical stains that were positive for glial fibrillary acidic protein and S100.
  • [MeSH-major] Astrocytoma / veterinary. Hedgehogs. Spinal Cord Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984799.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Dreyfuss JM, Johnson MD, Park PJ: Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer; 2009 Sep 04;8:71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.
  • BACKGROUND: Anaplastic astrocytoma (AA) and its more aggressive counterpart, glioblastoma multiforme (GBM), are the most common intrinsic brain tumors in adults and are almost universally fatal.
  • A deeper understanding of the molecular relationship of these tumor types is necessary to derive insights into the diagnosis, prognosis, and treatment of gliomas.
  • Although genomewide profiling of expression levels with microarrays can be used to identify differentially expressed genes between these tumor types, comparative studies so far have resulted in gene lists that show little overlap.
  • CONCLUSION: We have performed a meta-analysis of genome-scale mRNA expression data for 289 human malignant gliomas and have identified a list of >900 probe sets and >20 pathways that are significantly different between GBM and AA.
  • These feature lists could be utilized to aid in diagnosis, prognosis, and grade reduction of high-grade gliomas and to identify genes that were not previously suspected of playing an important role in glioma biology.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1371-7 [10604735.001]
  • [Cites] Mol Endocrinol. 2000 Jun;14(6):848-62 [10847587.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20315-23 [10783396.001]
  • [Cites] BMC Bioinformatics. 2008;9:63 [18226260.001]
  • [Cites] Genomics. 2008 May;91(5):395-406 [18343632.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 5;373(4):539-44 [18590702.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] BMC Bioinformatics. 2009;10:1 [19118496.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] FASEB J. 2001 Feb;15(2):458-66 [11156961.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1279-92 [11943713.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1695-700 [12414516.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]
  • [Cites] Acta Neuropathol. 2003 Jan;105(1):49-57 [12471461.001]
  • [Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Genome Biol. 2003;4(4):210 [12702200.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] Bioinformatics. 2003;19 Suppl 1:i84-90 [12855442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):615-21 [15122300.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):895-900 [10029081.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3915-8 [10463582.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 25;5:159 [15504239.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3166-78 [15231529.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Nat Methods. 2005 May;2(5):345-50 [15846361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9 [16174746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Bioinform Comput Biol. 2005 Oct;3(5):1171-89 [16278953.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):55-65 [16369572.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Biom J. 2006 Jun;48(3):435-50 [16845907.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10296-303 [17974971.001]
  • [Cites] Neurosurg Rev. 2008 Jan;31(1):83-9; discussion 89-90 [17917751.001]
  • [Cites] Comput Biol Chem. 2008 Feb;32(1):38-46 [17988949.001]
  • [Cites] Bioinformatics. 2008 Feb 1;24(3):374-82 [18204063.001]
  • [Cites] Ann Vasc Surg. 2008 Mar;22(2):273-84 [18346582.001]
  • (PMID = 19732454.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM082798; United States / NIH HHS / OD / DP2 OD002319; United States / NIH HHS / OD / DP2OD002319; United States / NLM NIH HHS / LM / U54 LM008748; United States / NLM NIH HHS / LM / U54LM008748
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2743637
  •  go-up   go-down


68. Wacker A, Will BE, Schöning M, Neunhoeffer F: [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma]. Z Geburtshilfe Neonatol; 2008 Oct;212(5):194-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma].
  • BACKGROUND: Anaplastic astrocytomas in neonates are extremely rare.
  • No tumour was found, but an anaplastic astrocytoma (WHO Grade III) was diagnosed histologically.
  • CONCLUSION: Congenital anaplastic astrocytomas have a variable outcome, with different survival rates as compared to adults.
  • [MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Cerebral Hemorrhage / congenital

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956278.001).
  • [ISSN] 0948-2393
  • [Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie
  • [ISO-abbreviation] Z Geburtshilfe Neonatol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S: Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg; 2007 Apr;106(4):575-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases.
  • OBJECT: The purpose of this retrospective study was to estimate the prognostic impact of treatment parameters for 170 patients with anaplastic astrocytoma (AA).
  • Resection of as much of the tumor as possible and delivery of a total radiation dose of greater than 60 Gy seem to be required for local control of AA.
  • [MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432706.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Walid MS, Troup EC: Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease. J Neurooncol; 2008 Aug;89(1):59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease.
  • We are presenting a young patient with Ollier Disease and high-grade astrocytoma.
  • Brain MRI with contrast showed a 41 x 55 mm mass in the posterior fossa with spotty enhancement, which pathology proved to be anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / etiology. Astrocytoma / pathology. Cerebellar Neoplasms / etiology. Cerebellar Neoplasms / pathology. Cerebellum / pathology. Enchondromatosis / complications
  • [MeSH-minor] Adolescent. Age Factors. Bone Neoplasms / diagnostic imaging. Bone Neoplasms / pathology. Chondroma / diagnostic imaging. Chondroma / pathology. Genetic Predisposition to Disease / genetics. Headache / etiology. Humans. Humerus / diagnostic imaging. Humerus / pathology. Magnetic Resonance Imaging. Male. Mutation / genetics. Neurosurgical Procedures. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. Radiography. Receptor, Parathyroid Hormone, Type 1 / genetics. Receptor, Parathyroid Hormone, Type 1 / metabolism. Scapula / diagnostic imaging. Scapula / pathology. Treatment Outcome. Vomiting / etiology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Ollier disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2005 Sep;167(3):859-67 [16127163.001]
  • [Cites] J Laryngol Otol. 2001 Oct;115(10 ):845-7 [11668006.001]
  • [Cites] Orphanet J Rare Dis. 2006 Sep 22;1:37 [16995932.001]
  • [Cites] Saudi Med J. 2004 Sep;25(9):1261-3 [15448780.001]
  • [Cites] AJR Am J Roentgenol. 2001 Feb;176(2):289-96 [11159059.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):1-31 [12742153.001]
  • [Cites] Childs Nerv Syst. 1999 May;15(5):222-5 [10392492.001]
  • [Cites] Am J Med Genet A. 2004 Oct 1;130A(2):123-7 [15372512.001]
  • [Cites] Brain Res. 2000 Jun 23;868(2):230-40 [10854575.001]
  • [Cites] J Bone Joint Surg Am. 1987 Feb;69(2):269-74 [3805090.001]
  • [Cites] Clin Neurol Neurosurg. 1999 Jun;101(2):106-10 [10467905.001]
  • (PMID = 18414790.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PTH1R protein, human; 0 / Receptor, Parathyroid Hormone, Type 1; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human
  •  go-up   go-down


71. Matar E, Cook RJ, Fowler AR, Biggs MT, Little NS, Wheeler HR, Robinson BG, McDonald KL: Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma. J Clin Neurosci; 2010 Aug;17(8):993-6
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma.
  • Diagnosis of an anaplastic astrocytoma (World Health Organization grade III) is associated with a highly variable prognosis.
  • In this study, we analysed 48 patients with a histological diagnosis of anaplastic astrocytoma and found peritumoral post-gadolinium contrast enhancement to be a clear prognostic marker of poor prognosis.
  • Multivariate analysis also confirmed surgery type, Karnofsky Performance Status score (<70) and increasing age as independent adverse predictors of survival.
  • The survival differences observed in the enhancing and non-enhancing lesions in patients diagnosed with anaplastic astrocytoma supports the existence of a broad anaplastic spectrum of disease, with enhancement being a clinical marker of tumour progression along this spectrum.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gadolinium. Image Enhancement

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605464.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


72. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T: MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res; 2010 Aug 15;16(16):4289-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance.
  • They are implicated in tumorigenesis and function both as tumor suppressors and as oncogenes.
  • The clinical significance of miRNA expression profiles in malignant gliomas remains unclear.
  • EXPERIMENTAL DESIGN: In this study, we examined the expression levels of 365 mature human miRNAs in 12 malignant gliomas, including 8 glioblastomas and 4 anaplastic astrocytomas, using TaqMan real-time quantitative PCR arrays.
  • A validation study was done to corroborate a subset of the results, including expression levels of miR-196a, -196b, -21, and -15b, by analyzing 92 malignant gliomas by conventional real-time PCR.
  • RESULTS: Expression profiles in glioblastomas and anaplastic astrocytomas suggested that 16 miRNAs were candidate markers associated with the malignant progression of gliomas.
  • Both miRNAs showed increased expression levels in glioblastomas relative to both anaplastic astrocytomas and normal brains in the validation study.
  • CONCLUSIONS: Our results suggest that miR-196 may play a role in the malignant progression of gliomas and may be a prognostic predictor in glioblastomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics. MicroRNAs / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601442.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN196 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


73. Tsutsumi S, Abe Y, Yasumoto Y, Ito M: Anaplastic pleomorphic xanthoastrocytoma with a component of anaplastic astrocytoma presenting as skull base tumor followed by downward extracranial extension. Case report. Neurol Med Chir (Tokyo); 2010;50(12):1108-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic pleomorphic xanthoastrocytoma with a component of anaplastic astrocytoma presenting as skull base tumor followed by downward extracranial extension. Case report.
  • The patient underwent subtotal tumor resection.
  • Most of the tumor was located extraaxially, but a part of the tumor had invaded the temporal lobe, and had tightly adhered to the middle cerebral artery and its perforating vessels.
  • Histological examination revealed cellular pleomorphism with mitotic activity, focal necrosis, but lacking endothelial proliferation, consistent with anaplastic pleomorphic xanthoastrocytoma (PXA) with component of anaplastic astrocytoma.
  • Postoperatively, the patient underwent local irradiation and temozolomide administration, but the tumor relapsed 13 months later.
  • Second tumor resection was performed followed by gamma knife radiosurgery, but the residual tumor progressively grew, extending into the contralateral hemisphere, and formed an enormous mass in the left frontal lobe at 17 months.
  • Magnetic resonance imaging performed at 18 months revealed extracranial infiltration of the frontal tumor, through the cribriform plate, with enormous extension into the paranasal sinuses, nasal cavity, and orbit during the next month.
  • PXA with anaplastic appearance may have a component of anaplastic astrocytoma with more aggressive behavior.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Skull Base Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206189.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Nakamura M, Tsuji O, Fujiyoshi K, Watanabe K, Tsuji T, Ishii K, Matsumoto M, Toyama Y, Chiba K: Cordotomy for patients with thoracic malignant astrocytoma. J Neurosurg Spine; 2010 Oct;13(4):418-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cordotomy for patients with thoracic malignant astrocytoma.
  • OBJECT: The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment.
  • In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure.
  • METHODS: Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA).
  • In the 2 patients with GBM, cordotomy was performed 2 and 3 weeks after a partial tumor resection.
  • In the 2 patients with AA, the initial treatment consisted of partial tumor resection and subtotal resection combined with radiotherapy, and rostral tumor growth and progressive paralysis necessitated cordotomy 2 and 28 months later.
  • One patient with a secondary GBM underwent cordotomy; the GBM developed 1 year after subtotal resection and radiotherapy for a WHO Grade II astrocytoma.
  • In patients with thoracic GBM, even if paralysis is incomplete, cordotomy should be performed before the tumor disseminates through the CSF.
  • If the tumor persists, radiotherapy and chemotherapy are indicated, and cordotomy should be reserved for lesions growing progressively after such second-line treatments.
  • [MeSH-major] Astrocytoma / surgery. Cordotomy. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Encephalitis / etiology. Female. Glioblastoma / complications. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pain, Postoperative. Paraplegia / etiology. Paraplegia / surgery. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887138.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Cheong JH, Kim CH, Kim JM, Oh YH: Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report. Clin Neurol Neurosurg; 2010 Oct;112(8):701-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.
  • Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.
  • These tumors are defined as a variant of glioblastoma, and it can be developed by progression of the malignant glial cell tumors or primary tumors.
  • We report a rare case with gliosarcomatous recurrence of anaplastic astrocytoma with neurofibromatosis type 1 (NF-1) followed by chemoradiation therapy.
  • He underwent an osteoplastic craniotomy with total tumor resection.
  • Histopathology of the tumor showed findings corresponding with anaplastic astrocytoma.
  • MRI showed tumor recurrence in the original site of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20466481.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


76. Arslantas A, Artan S, Oner U, Müslümanoglu MH, Ozdemir M, Durmaz R, Arslantas D, Vural M, Cosan E, Atasoy MA: Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res; 2007;13(1):39-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.
  • To extend our understanding of potential stepwise genetic alterations that may underlie tumor progression from low-grade astrocytomas to glioblastomas, histopathologic and comparative genomic hybridization analyses were performed on tumor specimens from 68 primary lesions, including 40 glioblastomas, 10 anaplastic and 18 low-grade astrocytomas.
  • The number of aberrations per case increased towards the higher grade tumors (grade II: 1.66+/-1.49; grade III: 2.80+/-1.68; grade IV: 3.02+/-1.07; F=6.955, p=0.002).
  • A gain of 7/7q was common and the most frequently seen aberration in low-grade astrocytomas, whereas loss of 10q was the most frequently seen anomaly in anaplastic astrocytomas and glioblastomas.
  • Chromosome 10/10q deletion and combination of 1p, 19q and 17p deletions were specific to high-grade astrocytic tumors.
  • The genomic copy deletions of chromosomes 1p and 19q might provide an alternative mechanism in the genesis of astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosome Deletion. Glioblastoma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1397-401 [8137236.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Jan;43(1):12-8; discussion 19 [12568317.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8 [11939587.001]
  • [Cites] Mol Carcinog. 2003 Jan;36(1):6-14 [12503074.001]
  • [Cites] Hum Genet. 1993 Sep;92(2):169-74 [8370584.001]
  • [Cites] Front Biosci. 2003 May 01;8:e281-8 [12700122.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2A):577-9 [8017863.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):68-77 [15472895.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):117-23 [9213056.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1203-18 [8203461.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2927-33 [9205099.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):61-6 [10077222.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):424-8 [8595154.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1141-50 [12370766.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Hum Pathol. 2000 May;31(5):608-14 [10836301.001]
  • [Cites] Virchows Arch. 1995;427(2):113-8 [7582239.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6353-8 [7987828.001]
  • (PMID = 17387387.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol; 2009 Sep;118(3):401-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
  • Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.
  • Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.
  • Pilocytic astrocytomas carry a duplication at chromosome band 7q34 containing a BRAF-KIAA1549 gene fusion in the majority of cases.
  • IDH1 mutations are observed very frequently in adult astrocytomas and IDH2 mutations have been reported in some astrocytomas.
  • We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF-KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing.
  • Pilocytic astrocytomas contained the BRAF fusion in 49 cases (70%) but neither IDH1 nor IDH2 mutations.
  • Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.
  • Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis


78. Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE: A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol; 2005 Feb;71(3):301-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • PURPOSE: Therapy for high-grade gliomas remains unsatisfactory.
  • We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • PATIENTS AND METHODS: Adult patients with radiographic evidence of recurrent or progressive tumor following primary therapy were eligible for study.
  • Hematologic toxicity was common with 25 /% of patients experiencing grade III or IV leukopenia despite G-CSF support.
  • CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma.
  • The significant hematotoxicity encountered, however, cannot justify further investigation of this combination in patients with high grade brain tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Disease-Free Survival. Drug Resistance, Neoplasm / drug effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Leukopenia / chemically induced. Male. Middle Aged. Paclitaxel / administration & dosage. Recombinant Proteins. Thrombocytopenia / chemically induced. Topotecan / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):980-6 [12095566.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Oncologist. 2003;8(1):76-82 [12604734.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1964-5 [8656268.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):923-7 [11521796.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1893-900 [11283120.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):725-7 [8428353.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2230-7 [7545219.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Sep;48(3):188-96 [11592339.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20 [1331485.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2032-7 [9626200.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2066-71 [7636549.001]
  • [Cites] Biometrics. 1993 Sep;49(3):741-52 [8241370.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):539-43 [8120551.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):600-9 [8636777.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Drugs. 1995 Jan;49(1):11-9 [7705211.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):417-22 [11180089.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Expert Opin Pharmacother. 2001 Mar;2(3):491-505 [11336601.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9 [11516860.001]
  • (PMID = 15735921.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


79. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer; 2009 Jan;45(1):146-53
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
  • AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.
  • RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.
  • By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p<0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Methylation. Female. Glioblastoma / drug therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945611.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


80. Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS: Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg; 2006 Jul;105(1):34-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.
  • OBJECT: To investigate the prognostic significance of the volumetrically assessed extent of resection on time to tumor progression (TTP), overall survival (OS), and tumor recurrence patterns, the authors retrospectively analyzed preoperative and postoperative tumor volumes in 102 adult patients from the time of the initial resection of a hemispheric anaplastic astrocytoma (AA).
  • METHODS: The quantification of tumor volumes was based on a previously described method involving computerized analysis of magnetic resonance (MR) images.
  • Analysis of contrast-enhancing tumor volumes on T1-weighted MR images was conducted for 67 patients who had contrast-enhancing tumors.
  • The presence or absence of preresection enhancement, actual volume of this enhancement, and the percentage of preoperative enhancement as it relates to the total T2 tumor volume did not have a statistically significant relationship to TTP or OS.
  • In addition to age, the volume of residual disease measured on T2-weighted MR images was the most significant predictor of TTP (p < 0.001), and residual contrast-enhancing tumor volume was the most significant predictor of OS (p = 0.003) on multivariate analysis.
  • In contrast to low-grade gliomas, there was no statistically significant relationship between the extent of resection and histological characteristics at the time of recurrence, that is, tumor Grade III compared with Grade IV.
  • CONCLUSIONS: Data from this retrospective analysis of a histologically uniform group of hemispheric AAs treated in the MR imaging era suggest that residual tumor volumes, as documented on postoperative imaging studies, may be a prognostic factor for TTP and OS for this patient population.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm, Residual. Predictive Value of Tests. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871879.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


81. Chang CL: Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme. J Biomol Screen; 2008 Oct;13(9):912-21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme.
  • The gene-expression profiles of approximately 20,000 genes from 4 anaplastic astrocytomas (AAs), 7 glioblastoma multiformes (GBMs), and 1 nontumor brain (NB) were analyzed by in situ-synthesized 60-mer oligonucleotide microarray.
  • The signal intensity of each feature was measured by laser scanner, and gene expression was quantified as the tumor/NB intensity ratio.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genome, Human. Glioblastoma / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812569.001).
  • [ISSN] 1087-0571
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Oligonucleotides
  •  go-up   go-down


82. Momota H, Narita Y, Miyakita Y, Hosono A, Makimoto A, Shibui S: Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer; 2010 Sep;55(3):577-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
  • We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ).
  • Although alkylating agents such as TMZ are known to induce secondary hematologic malignancy, only several cases of treatment-related acute leukemia have been reported after TMZ-alone chemotherapy for malignant gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Frontal Lobe. Genes, p53 / genetics. Germ-Line Mutation. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2011 Mar;56(3):509. Nariata, Yoshitaka [corrected to Narita, Yoshitaka]
  • (PMID = 20658636.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


83. Nishikawa R, Shibui S, Maruno M, Sugiyama K, Sato S, Fujimaki T, Takahashi H, Wakabayashi T, Takahashi J, Kochi M, Nakamura H, Sawamura Y, Ikeda J, Hori T, Aoki T, Matsutani M: [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1279-85
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
  • The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse.
  • The main laboratory test abnormalities (total incidence and incidence of grade 3/4 change) were lymphocytopenia (50%, 25%), neutropenia (47%, 6%), leukopenia (38%, 3%), thrombocytopenia (31%, 9%), and increased GPT (25%, 3%).
  • Temozolomide was shown to have good efficacy and tolerability in patients with anaplastic astrocytoma at first relapse.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969025.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


84. Muthukrishnan A, Bajoghli M, Mountz JM: Delayed development of radiation vasculopathy of the brain stem confirmed by F-18 FDG PET in a case of anaplastic astrocytoma. Clin Nucl Med; 2007 Jul;32(7):527-31
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed development of radiation vasculopathy of the brain stem confirmed by F-18 FDG PET in a case of anaplastic astrocytoma.
  • We present the imaging findings of a 38-year-old female patient who underwent resection and radiation therapy for an anaplastic astrocytoma in her left temporal lobe 12 years ago.
  • Since viable tumor recurrence was strongly suspected, a biopsy was planned, although this posed significant risk.
  • This case illustrates the importance of considering the rare diagnosis of radiation-induced vasculopathy in the differential diagnosis when symptoms of recurrent brain tumor occur.
  • [MeSH-minor] Adult. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Female. Humans. Positron-Emission Tomography / methods. Radiopharmaceuticals. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581336.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. See SJ, Ty A, Wong MC: Salvage chemotherapy in progressive high-grade astrocytoma. Ann Acad Med Singapore; 2007 May;36(5):343-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy in progressive high-grade astrocytoma.
  • INTRODUCTION: Despite aggressive multidisciplinary interventions, patients with high-grade astrocytomas experience tumour progression or recurrence.
  • MATERIALS AND METHODS: A retrospective review of relevant clinical and radiographic information of patients who received at least one cycle of salvage chemotherapy for progressive high-grade astrocytoma at the National Cancer Center, Singapore, from March 2004 to September 2006, was conducted.
  • RESULTS: Twenty-four patients (13 glioblastomas, 11 anaplastic astrocytomas) had received chemotherapy as salvage treatment following progression of their high-grade astrocytoma.
  • For patients with anaplastic astrocytoma, the 12-month survival rate was 73%.
  • CONCLUSION: Durable disease control and prolonged survival were seen in a significant portion of selected patients with progressive high-grade astrocytoma who received salvage chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Glioblastoma / drug therapy. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549281.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


86. Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A: A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest; 2008 Apr-May;26(3):269-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
  • This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m2/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles.
  • Grade 3 and 4 lymphopenia occurred in 53% and 47% of patients, respectively.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy


87. Chamberlain MC, Chowdhary SA, Glantz MJ: Anaplastic astrocytomas: biology and treatment. Expert Rev Neurother; 2008 Apr;8(4):575-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytomas: biology and treatment.
  • Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms.
  • The most important predictor of response to therapy and survival in AA tumors is the presence or absence of the 1p19q co-deletion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416660.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Yeh S, Fine HA, Smith JA: Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea; 2009 Jul;28(6):699-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
  • PURPOSE: To describe a patient with a history of epithelial basement membrane dystrophy who developed symptomatic corneal verticillata after vandetanib therapy for anaplastic astrocytoma.
  • RESULTS: A 48-year-old female patient with a history of anaplastic astrocytoma status post resection, external beam radiation, and chemotherapy presented with glare symptoms, decreased contrast sensitivity, and increased lacrimation after approximately 12 months of therapy with the anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor, vandetanib.
  • The patient remained under surveillance for tumor recurrence.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Corneal Diseases / chemically induced. Neoplasm Recurrence, Local / drug therapy. Piperidines / adverse effects. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19512898.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Ointments; 0 / Piperidines; 0 / Quinazolines; 451W47IQ8X / Sodium Chloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.2.1.4 / Cellulase; EC 3.2.1.4 / carboxymethylcellulase
  •  go-up   go-down


89. Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, Vredenburgh J, Quinn J, Friedman HS: Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol; 2008 Feb;10(1):93-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.
  • We describe the case of a patient with transcobalamin II deficiency, hypogammaglobulinemia, absent corpus callosum, and mental retardation who presented at an early age with colorectal cancer and multifocal anaplastic astrocytoma.
  • He was found to have a possible germline mutation of the PMS2 gene, as evidenced by absent protein expression in both normal and tumor tissues.
  • [MeSH-major] Abnormalities, Multiple / genetics. Adenosine Triphosphatases / genetics. Astrocytoma / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics


90. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF: Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell; 2005 Aug;8(2):119-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
  • Malignant astrocytoma, the most prevalent primary brain tumor, is resistant to all known therapies and frequently harbors mutations that inactivate p53 and activate Ras signaling.
  • We have generated mouse strains that lack p53 and harbor a conditional allele of the NF1 tumor suppressor that negatively regulates Ras signaling.
  • The mice develop malignant astrocytomas with complete penetrance.
  • The majority of tumors display characteristics of glioblastoma multiforme with concomitant alteration of signaling pathways previously described in the human counterparts of this neoplasm.
  • We find that the sequence of tumor suppressor inactivation influences tumorigenicity and that earliest evidence of tumor formation localizes to regions of the brain that contain a multipotent stem cell population capable of in vivo differentiation into neurons and glia.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2121-7 [8668337.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Microsc Res Tech. 1998 Jun 1;41(5):344-58 [9672418.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Curr Opin Neurobiol. 1999 Feb;9(1):135-41 [10072370.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17528-32 [15574494.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Neuron. 2000 Feb;25(2):317-29 [10719888.001]
  • [Cites] Neuron. 2000 Feb;25(2):331-43 [10719889.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):19-28 [11237520.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Cereb Cortex. 2003 Jun;13(6):580-7 [12764031.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4305-9 [12907595.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Curr Opin Neurobiol. 2002 Jun;12(3):244-9 [12049929.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):157-68 [12086874.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):759-61 [12221173.001]
  • [Cites] J Cell Biochem. 2003 Jan 1;88(1):11-9 [12461769.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13008-13 [15319471.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):3910-8 [2454731.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2987-90 [1349850.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Jan;52(1):31-8 [8381161.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1324-30 [8118823.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 6;86(13):1011-7 [8007011.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):613-24 [11300931.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3826-36 [11325859.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • (PMID = 16098465.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS034296-07; United States / NINDS NIH HHS / NS / NS034296-07; United States / NCI NIH HHS / CA / P20 CA086354; United States / NINDS NIH HHS / NS / R01 NS034296-06; United States / NINDS NIH HHS / NS / R01 NS034296; United States / NINDS NIH HHS / NS / NS034296-06; United States / NCI NIH HHS / CA / P20 CA86354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS263629; NLM/ PMC3024718
  •  go-up   go-down


91. Williams G, Fahey FH, Treves ST, Kocak M, Pollack IF, Boyett JM, Kun LE, Poussaint TY: Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC). Eur J Nucl Med Mol Imaging; 2008 Sep;35(9):1651-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC).
  • PURPOSE: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze (18)F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS).
  • METHODS: 3D tumor volumes from pretreatment MR images (fluid attenuation inversion recovery and postgadolinium) of children with recurrent AA on a phase I trial of imatinib mesylate were co-registered to FDG positron emission tomography (PET) images.
  • Four metrics were defined: the maximum ratio (maximum pixel value within the 3D tumor volume, normalized), the total ratio (cumulative pixel values within the tumor volume, normalized) and tumor mean ratio (total pixel value divided by volume, normalized).
  • The analyses suggest 3D maximum tumor and mean tumor ratios, whether normalized by gray matter or white matter, were associated with PFS.
  • These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined.
  • [MeSH-major] Astrocytoma / diagnostic imaging. Brain Neoplasms. Fluorodeoxyglucose F18. Imaging, Three-Dimensional / methods. Organizations. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Clinical Trials, Phase I as Topic. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Phantoms, Imaging. Prognosis. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Apr;28(4):603-7 [17416804.001]
  • [Cites] Mol Imaging Biol. 2006 May-Jun;8(3):141-50 [16534552.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Neurosurgery. 1996 Sep;39(3):470-6; discussion 476-7 [8875476.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3234-44 [16829647.001]
  • [Cites] Radiology. 1995 Apr;195(1):47-52 [7892494.001]
  • [Cites] J Clin Oncol. 2005 May 1;23 (13):3030-7 [15860860.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] Clin Positron Imaging. 2000 Jul;3(4):152 [11150755.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jul-Aug;21(4):554-66 [9216759.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12 (4):615-26 [12687915.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):816-22 [2987440.001]
  • (PMID = 18425516.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UM1 CA081457; United States / PHS HHS / / U01 A 81457
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Chaichana KL, Kosztowski T, Niranjan A, Olivi A, Weingart JD, Laterra J, Brem H, Quiñones-Hinojosa A: Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosurg; 2010 Aug;113(2):286-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults.
  • OBJECT: Patients harboring anaplastic astrocytomas (AAs) typically have a poor prognosis, with median survival times of approximately 3 years following resection.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Contrast Media. Craniotomy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302391.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


93. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ, EORTC Brain Tumour Group investigators: Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer; 2008 Jun;44(9):1210-6
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
  • BACKGROUND: In a previous randomised EORTC study on adjuvant dibromodulcitol (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overall survival (OS) and a progression-free survival (PFS) was observed in the subgroup of AA.
  • METHODS: Continuation of the previous phase III trial for newly diagnosed AA according to the local pathologist.
  • Central pathology review of grade 3 tumours remains crucial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248979.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 11488
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] LJ2P1SIK8Y / Mitolactol; U68WG3173Y / Carmustine
  • [Investigator] Afra D; Maat B; Hildebrand J; de Wit O; Frenay F; Chatel M; Rivier I; Taphoorn M; Delattre JY; de Tribolet N; Stupp R; Punt J; Garfield J; Chinot O; van den Bent M; Lahrmann H; Cristo C; Mouchamps M; Haferkamp G; Bravo Marques J
  •  go-up   go-down


94. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R: A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol; 2005 May;72(3):241-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
  • Two types of chemotherapy used in the treatment of patients with malignant glioma are carboplatin and Gliadel wafer [(3.85% 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)].
  • The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma.
  • Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma.
  • No grade 3 or 4 toxicities were noted in this study.
  • We conclude that administering systemic carboplatin is safe and well tolerated in the postoperative period immediately following resection and implantation of Gliadel wafer for the treatment of malignant glioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carboplatin / therapeutic use. Decanoic Acids / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Polyesters / therapeutic use
  • [MeSH-minor] Adult. Aged. Carmustine. Combined Modality Therapy. Disease Progression. Drug Implants. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):619-25 [11148660.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Neurosurgery. 1992 Feb;30(2):223-7 [1312230.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):672-84 [9485020.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] Neuro Oncol. 2001 Oct;3(4):246-50 [11584894.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(4):376-9 [9025780.001]
  • [Cites] J Control Release. 1999 Aug 27;61(1-2):21-41 [10469900.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 15937647.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


95. Nagai S, Kurimoto M, Washiyama K, Hirashima Y, Kumanishi T, Endo S: Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol; 2005 Sep;74(2):105-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines.
  • In malignant astrocytoma cells, it was reported that NF-kappaB was activated aberrantly and promoted their proliferation.
  • Thus, inhibition of NF-kappaB activity is considered to be a promising therapeutic strategy for malignant astrocytoma.
  • In this study, we investigated inhibitory effects of curcumin on NF-kappaB activity and cellular proliferation, and induction of apoptosis by curcumin in human malignant astrocytoma cell lines.
  • Alteration of NF-kappaB activity in NP-2 human malignant astrocytoma cell line after treatment with curcumin was examined using electrophoretic mobility shift assay.
  • Alterations of DNA synthesis and cellular growth in five human malignant astrocytoma cell lines after treatment with curcumin were examined using [(3)H]thymidine incorporation assay and the trypan blue dye exclusion method, respectively.
  • Induction of apoptosis by curcumin in NP-2 and NP-3 human malignant astrocytoma cell lines was examined by DNA-fragmentation analysis and morphological observation.
  • The DNA synthesis and the cellular growth were inhibited by curcumin in dose-dependent manner in all the five malignant astrocytoma cell lines.
  • These results indicate that curcumin inhibits the cellular proliferation and induces apoptosis in human malignant astrocytoma cell lines.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Astrocytoma / drug therapy. Cell Proliferation / drug effects. Curcumin / therapeutic use. NF-kappa B / drug effects
  • [MeSH-minor] Electrophoretic Mobility Shift Assay. Humans. Thymidine / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2002 May;96(5):909-17 [12005399.001]
  • [Cites] Surg Oncol. 1999 Nov;8(3):143-53 [11113665.001]
  • [Cites] Hum Exp Toxicol. 2003 Dec;22(12):653-8 [14992327.001]
  • [Cites] FEBS Lett. 1999 Feb 19;445(1):165-8 [10069393.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5841-7 [7954412.001]
  • [Cites] Neurobiol Aging. 2001 Nov-Dec;22(6):993-1005 [11755008.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):247-54 [10359144.001]
  • [Cites] Life Sci. 2004 Jan 9;74(8):969-85 [14672754.001]
  • [Cites] J Clin Invest. 2001 Jan;107(2):135-42 [11160126.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):387-97 [11485895.001]
  • [Cites] Mol Cell Biol. 1992 Oct;12(10):4412-21 [1406630.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):259-66 [7812955.001]
  • [Cites] Nature. 1995 Jul 13;376(6536):167-70 [7603567.001]
  • [Cites] Free Radic Biol Med. 2003 Dec 15;35(12):1632-44 [14680686.001]
  • [Cites] Anticancer Drugs. 1997 Jun;8(5):470-81 [9215611.001]
  • [Cites] Phytother Res. 1999 Nov;13(7):571-4 [10548748.001]
  • [Cites] J Lab Clin Med. 1997 Dec;130(6):576-84 [9422331.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2690-8 [10082535.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):5941-6 [3139287.001]
  • [Cites] Planta Med. 1991 Feb;57(1):1-7 [2062949.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] Acta Neuropathol. 1988;76(5):433-40 [3188836.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15601-4 [10747850.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):363-98 [12680238.001]
  • [Cites] Pharmacol Res. 2002 Sep;46(3):273-9 [12220971.001]
  • [Cites] J Immunol. 1999 Sep 15;163(6):3474-83 [10477620.001]
  • [Cites] J Neurosci. 2001 Nov 1;21(21):8370-7 [11606625.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8852-61 [12483537.001]
  • (PMID = 16193380.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; IT942ZTH98 / Curcumin; VC2W18DGKR / Thymidine
  •  go-up   go-down


96. Bozinov O, Köhler S, Samans B, Benes L, Miller D, Ritter M, Sure U, Bertalanffy H: Candidate genes for the progression of malignant gliomas identified by microarray analysis. Neurosurg Rev; 2008 Jan;31(1):83-9; discussion 89-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate genes for the progression of malignant gliomas identified by microarray analysis.
  • Malignant astrocytomas of World Health Organization (WHO) grade III or IV have a reduced median survival time, and possible pathways have been described for the progression of anaplastic astrocytomas and glioblastomas, but the molecular basis of malignant astrocytoma progression is still poorly understood.
  • We compared the transcriptional profile of 4,608 genes in tumours of 15 patients including 6 anaplastic astrocytomas (WHO grade III) and 9 glioblastomas (WHO grade IV) using microarray analysis.
  • We identified 166 gene alterations with a fold change of 2 and higher whose mRNA levels differed (absolute value of the t statistic of 1.96) between the two malignant glioma groups.
  • Further analyses confirmed same transcription directions for Olig2 and IL-13Ralpha2 in anaplastic astrocytomas as compared to glioblastomas.
  • IL-13Ralpha2 and Olig2 have been identified and confirmed to be interesting candidate genes whose differential expression likely plays a role in malignant progression of astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Expression Profiling. Glioblastoma / genetics. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Neurosurg Rev. 2008 Apr;31(2):247-8
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Mol Med. 2000 May;6(5):440-9 [10952023.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Methods. 2001 Dec;25(4):386-401 [11846608.001]
  • [Cites] Blood. 2001 May 1;97(9):2673-9 [11313257.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2508-18 [12839017.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 May;63(5):499-509 [15198128.001]
  • [Cites] J Cell Biol. 2004 Sep 27;166(7):963-8 [15452140.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):108-16 [11771519.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):783-7 [12939468.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):196-202 [14576772.001]
  • [Cites] Life Sci. 1997;60(1):13-9 [8995527.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):843-6 [15731001.001]
  • [Cites] Acta Neuropathol. 2004 Mar;107(3):277-82 [14730454.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1743-54 [11748276.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Neuropathology. 2005 Mar;25(1):1-7 [15822813.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10851-6 [11526205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3497-502 [10737801.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):161-76 [11716068.001]
  • [Cites] Cell. 2002 Apr 5;109(1):61-73 [11955447.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Feb;31(1):62-9 [15634232.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):193-202 [15838375.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1036-42 [15329913.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7902-12 [16103881.001]
  • (PMID = 17917751.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


97. Kawarabuki K, Ohta T, Hashimoto N, Wada K, Maruno M, Yamaki T, Ueda S: Cerebellar glioblastoma genetically defined as a secondary one. Clin Neuropathol; 2005 Mar-Apr;24(2):64-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present case, tumor lesions were observed in each cerebellar hemisphere.
  • The left-side lesion was diagnosed as glioblastoma, and the right-side lesion as malignant astrocytoma by histopathology.
  • Immunohistochemistry revealed that the tumor cells of the left-side lesion was positive for p53, whereas epidermal growth factor receptors (EGFR) were negative in tumor cells from both sides.
  • Genetic alterations were investigated using a genome DNA microarray (GenoSensor Array 300), which has led us to define this tumor as a secondary glioblastoma.

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803805.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Buckner JC, O'Fallon JR, Dinapoli RP, Schomberg PJ, Farr G, Schaefer P, Giannini C, Scheithauer BW, Ballman KV: Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. J Neurooncol; 2007 Sep;84(3):279-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.
  • BACKGROUND: Anaplastic oligoastrocytomas (AOA) are relatively uncommon high-grade gliomas.
  • METHODS: Between 1980 and 1999, Mayo Clinic and the NCCTG conducted 10 trials of radiation therapy and chemotherapy in adults with newly-diagnosed high-grade gliomas.
  • We grouped patients by cell type and grade, compared survival distributions by the log-rank statistic, and performed multiple variable analyses.
  • RESULTS: Of 1368 patients, 68 (5%) had AOA, including 21 Grade 3 (OA3) and 47 grade 4 (OA4), 153 (11%) had anaplastic astrocytoma (AA), and 1147 (84%) had glioblastoma multiforme (GBM).
  • CONCLUSIONS: Patients with anaplastic oligoastrocytoma have distinct outcomes based upon grade (OA3 vs. OA4) and in comparison with pure astrocytoma (AA or GBM).
  • Future trials which include more than one histologic entity need to report results by cell type and grade and account for the varying prognoses in interpreting treatment outcomes.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Biometrics. 1992 Jun;48(2):411-25 [1637970.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):577-82; discussion 582 [8008153.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • (PMID = 17431544.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Wu-Chen WY, Jacobs DA, Volpe NJ, Dalmau JO, Moster ML: Intracranial malignancies occurring more than 20 years after radiation therapy for pituitary adenoma. J Neuroophthalmol; 2009 Dec;29(4):289-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging disclosed a left parasellar mass and a midbrain/pontine signal abnormality.
  • Biopsy of the parasellar mass revealed a malignant sarcoma.
  • The brainstem abnormality was presumptively diagnosed as a malignant glioma.
  • A 63-year-old man developed a malignant astrocytoma of the left optic nerve and chiasm 23 years after partial excision and radiation of a nonsecreting pituitary adenoma.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952902.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Kojadinovic Z, Papic V, Cigic T, Vulekovic P, Popovic Lj, Jajic Dj: A new scoring system for malignant astrocytomas. Zentralbl Neurochir; 2008 May;69(2):65-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new scoring system for malignant astrocytomas.
  • BACKGROUND: Currently there are a few scoring systems for malignant astrocytoma, but they are not widely accepted.
  • The aim of this study was to create a scoring system for supratentorial malignant astrocytoma, which could be used in both developed and developing societies.
  • METHODS: This study was performed in 128 patients who had supratentorial malignant astrocytoma (grade III or IV).
  • By using the most appropriate four parameters (age, KPS, initial seizure and histopathological grade) we created a scoring system - MAS (Malignant Astrocytoma Score).
  • CONCLUSIONS: We are of the opinion that MAS represents a useful scoring system to determine the severity of the illness and make a prognosis for both individuals and groups of patients with malignant supratentorial astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures / mortality. Prognosis. Proportional Hazards Models. ROC Curve. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444219.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement